Genetic Manipulation of FBP1 Expression in Breast Cancer Cells Reveals the Potential of FBP1 to Disrupt The Warburg Effect, and Nutrient Mediated Adaptive Post-Translational Regulation of FBP1 Protein Levels.

Genetic Manipulation of FBP1 Expression in Breast Cancer Cells Reveals the Potential of FBP1 to Disrupt The Warburg Effect, and Nutrient Mediated Adaptive Post-Translational Regulation of FBP1 Protein Levels. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Genetic Manipulation of FBP1 Expression in Breast Cancer Cells Reveals the Potential of FBP1 to Disrupt The Warburg Effect, and Nutrient Mediated Adaptive Post-Translational Regulation of FBP1 Protein Levels. Ali Ghanem, Boilinh Troung, Stefan Wölfl This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1030616/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract The key gluconeogenic enzyme Fructose 1,6 bisphosphatase has emerged as a potential metabolic tumour suppressor in recent years. Ablation of FBP1 expression in various tumours fosters metabolic rewiring towards an increased reliance on aerobic glycolysis. While FBP1 is completely repressed in many cancers, breast tumours display distinct FBP1 expression based on their subtype, hence making breast cancer a suitable model for discerning the effects of FBP1 in contexts of cancer initiation and progression. We used ectopic over-expression and CRISPR-Cas9 disruption to establish cell lineages with stable alterations in their FBP1 levels. Complete knock-outs of FBP1 on gene level confirm the major impact of FBP1 on cancer cell metabolism and proliferation. Moreover, our results reveal cancer subtype-specific peculiarities in response to ectopic FBP1 expression including a clear demonstration of an adaptive proteasomal degradation of FBP1 in breast cancer cells, which is regulated by glucose and nutrient availability. In addition to validating the suggested tumour suppressor role of FBP1, our findings demonstrate an efficient adaptive complex regulation of FBP1 expression and its impact on the adaptation of cancer cells to nutrient conditions. Our results highlight the importance of FBP1 ablation on the protein level and its potential relevance to cancer and beyond. Cancer Biology Cellular Metabolism gluconeogenic metabolic suppressor cancers breast tumours Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Summary/ Highlights FBP1 is a quasi-tumor suppressor, whose levels diminish with cancer initiation and/or progression. FBP1 expression inhibits glucose uptake and metabolism and promotes respiration and mitochondrial activity. The loss of FBP1 fosters the Warburg effect. We describe an additional layer of FBP1 depletion on the post translational level. Cells with diminished FBP1 use the proteasome system to degrade the FBP1 protein; this is reversible and happens only in the presence of glucose. This mechanism is reminiscent of the FBP1 regulation in yeast, required for rapid adjustment to nutrient availability and growth conditions. The glucose-mediated proteasomal degradation of FBP1 allows a self-propagating cycle of increased glucose uptake leading to further repression of FBP1, which in turn allows for increased glucose uptake. Consistently, higher levels of FBP1 correlated with broad inhibition of cell cycle factors especially belonging to the G2/M phase. Introduction Recent years have seen a surge in research exploring the relevance of gluconeogenesis and the key enzyme fructose-1,6-bis-phosphatase FBP1 in cancer contexts [ 1 – 5 ]. The epigenetic silencing of FBP1 has been observed in several types of tumours and linked to poorer prognoses [ 2 , 3 , 5 – 9 ]. For many cancers, the loss of FBP1 has been described as an advantageous event in the metabolic rewiring towards aerobic glycolysis. However, some cancer types show ambivalence in their FBP1 expression, with FBP1 expression maintained in less critical lesions and FBP1-loss having a poor prognostic relevance[ 2 ]. Breast tumours with better survival rates show positive FBP1 expression, while the more advanced forms of basal-like, triple-negative and metastatic breast cancer lack FBP1 expression. [ 9 , 10 ]. This heterogeneity of breast cancers in regard to FBP1 expression makes breast cancer cells an apt model to further investigate the effects and regulation of FBP1 in contexts of cancer. To address this issue, we established stable over-expressions and a CRISPR-Cas9 knock-out of FBP1 in cultured breast cancer cell lines representing the two major subtypes; luminal (MCF-7) and basal-like (MDA-MB-231) (Fig S1) to investigate the impact of FBP1 in breast cancer with emphasis on the particularities of the two cellular environments. This was achieved by characterising the proliferative, metabolic, and oxidative effects of stable FBP1 over-expression and knock-out. We demonstrate evidence of non-genomic FBP1-repression promoting further metabolic reprogramming to foster the Warburg effect, including increased aerobic fermentation, and glucose catabolism through both the glycolytic and pentose phosphate pathways, in addition to an increase in the levels of particular amino acids derived from both pathways. Our findings signify clear distinctions between the two cell types in their reaction to ectopic FBP1. Our findings demonstrate an important role for post-translational regulation of FBP1 levels in breast cancer cells by protein degradation, and the modulation of FBP1 levels based on nutrient availability in the medium. The emergence of CRSPR-Cas9 as a highly malleable and adaptable tool has made precise gene editing more feasible than ever before [ 11 , 12 ], and opened the avenue for new genetic screens and precise genomic target validation and confirmation of findings based on non-genomic interference studies (i.e. siRNA) [ 12 – 14 ]. Using CRISPR-Cas9 mediated gene knock out to generate a genomic deletion of FBP1 in cancer cells we observed some clear differences to all previous studies using shRNA or siRNA mediated knock-downs [ 1 – 5 ]. The results obtained further demonstrate the essential role of FBP1 in metabolic adjustment and confirm the role of FBP1 as an emerging tumour suppressor, and emphasize FBP1’s potential to suppress cancer specific glycolysis driven metabolism. Results The ectopic expression of FBP1 slows down MCF-7 proliferation in presence of abundant glucose Previous reports indicated an anti-proliferative effect of FBP1 in various cancer types [ 1 – 3 , 5 – 7 ]. To assess the effect of FBP1 on proliferation, we used the protein-based SRB viability assay to assess the growth rate of stable MCF-7 lineages, in which we established various contexts of FBP1 (Fig S1). Cells with FBP1 over-expression exhibited slower growth than the vector control cells (Fig. 1 a). Consistently, knocking out FBP1 increased the growth rate of MCF-7 cells with stable CRISPR-Cas9 deletion compared to the unmodified wild type cells (Fig. 1 a). The changes in growth rates were not reflected in the colony formation assay (Fig. 1 c). This last finding indicates that FBP1 does not hamper tumorigenesis in this luminal breast cancer subtype, consistent with the positive FBP1 expression in primary and luminal breast cancers [ 2 ]. FBP1 is essential for glucose autotrophy in MCF-7 cells Our previous work on yeast established that FBP1 is indispensible for a continued gluconeogenesis flux [ 15 , 16 ]. We therefore assessed the proliferation and survival of FBP1-KO cells under glucose depletion. Glucose withdrawal specifically impacted FBP1-KO growth and survival while the wild-type cells continued proliferating. Complete glucose deprivation inhibited the proliferation of FBP1 KO cells starting at 3 days after glucose withdrawal (Fig. 1 b). Consistently, limiting glucose in medium to 2mM had comparable effects on FBP1-KO. On the contrary, neither diminished glucose nor complete glucose deprivation affected the proliferation of the wild type MCF-7 cells (Fig. 1 b). This result highlights both the indispensability of FBP1 activity for gluconeogenesis in MCF-7, and also ensures that FBP1 is the only isozyme in these cells capable of catalysing the dephosphorylation of F1,6bP. FBP1 inhibits glucose uptake under a variety of conditions in MCF-7 cells To test the impact of FBP1 on glucose uptake in MCF-7 cells, we used 2-NBDG (fluorescence labelled 2-DG). The over-expression of FBP1 inhibited glucose uptake in full DMEM, meanwhile FBP1 KO showed a general trend towards increased glycolysis (Fig. 2 a). FBP1 over-expression also inhibited glucose uptake upon glucose replenishment and under glutamine deprivation (Fig. 2 b)., consistent with the reports on the anti-glycolytic effect of FBP1 in various types of cancer [ 2 – 8 ]. FBP1 loss increases glucose utilisation in glycolysis, pentose phosphate pathway and amino acid synthesis In line with earlier reports on FBP1 repression as an essential step towards Warburg metabolic rewiring [ 2 , 3 , 5 ], we used HPLC-MS metabolite quantification to investigate the metabolic shifts in FBP1 KO MCF-7 cells in contrast with the parental wild-type cells. FBP1 KO cells demonstrated an increased abundance of glycolysis and pentose phosphate pathway intermediates (Fig. 2 c,d). Increased intracellular and extracellular lactate also indicates an increased glycolytic flux. Unlike the other glycolytic intermediates, phosphoenolpyruvate and pyruvate were both depleted in the FBP1 KO cells. The increase of the intracellular and extracellular lactate on expense of pyruvate is a clear sign of increased aerobic fermentation in the absence of FBP1 (Fig. 2 c,g). Since pyruvate the most net consumed metabolite by cells (Fig S2), the depletion of pyruvate in medium and the increase in intracellular and medium lactate strongly signifies an overall increase in pyruvate conversion to lactate fuelled by both glycolytic and extracellular pyruvate. Altogether this indicates glucose to lactate metabolic flux, hence a potentiated Warburg effect in the FBP1 KO cells. The depletion of pyruvate and phosphoenolpyruvate in FBP1 KO MCF-7 also coincided with an increase in alanine levels in medium, for which pyruvate is the biosynthetic precursor. Glutamine is the major nitrogen source and amino-acid in DMEM, with 2-D cultured cells showing higher reliance on glutamine compared to spheroids or in-vivo tumours [ 17 ]. The increased level of medium glutamine, observed for the MCF-7 KO cells (Fig. 2 g), signifies a shift from amino acid to glucose catabolism upon FBP1 loss. Consistently, the overall output of extracellular alanine, which is net released from the cells into the medium (Fig S2), is increased, hence signifying an increased overall amino acid biosynthesis. Moreover, leucine, isoleucine, valine, tyrosine, tryptophan and phenylalanine, all essential amino acids, showed elevated accumulation in FBP1 KO cells hence indicating increased uptake and/or decreased catabolism due to the complete inhibition of gluconeogenesis (Fig S2). A combination of GAPDH inhibition and of PKM2 activation causes serine depletion in FBP1 KO MCF-7 Intriguingly, and contrary to earlier findings [ 2 ], FBP1 KO correlated to a significant depletion of intracellular serine and its downstream derivative glycine (Fig. 2 f). This depletion was not accompanied by shifts of either serine or glycine medium concentrations hence ruling out changes of uptake or secretion (Fig S2), while the activity of PHGDH, the key enzyme for serine biosynthesis [ 18 ], remained unchanged (Fig S3). Changes in glycolytic enzymatic activity offer a plausible explanation for the unexpected depletion of serine in FBP1 KO cells. We detected inhibited GAPDH activity and increased pyruvate kinase activity in the native protein extracts of the FBP1 KO cells compared to wild type (Fig S3). GAPDH inhibition is a reported mechanism of fuelling the pentose phosphate shunt with G6P [ 19 – 21 ], and it consists with the observed increase of upper glycolytic (Fig. 2 c), and pentose phosphate pathway intermediates (Fig. 2 d). FBP1 substrate F1,6bP is a robustly established allosteric activator of PKM2 [ 22 , 23 ], hence the removal of FBP1 spares its substrate allowing the observed activation of PKM2. Together, inhibited GAPDH and activated PKM2 deplete the glycolytic intermediates in between the two enzyme, including 3-PG, the initial substrate of serine biosynthesis (Fig. 2 c&f). FBP1 impedes glucose sensing and uptake and in MCF-7 cells To further assess the impact of FBP1 on glucose sensing, we probed TXNIP expression. TXNIP expression is indirectly induced by the glycolytic intermediates Glucose-6-phosphate G6P and glyceraldehyde-3phosphate GA3P [ 24 ]. Hence TXNIP is completely depleted under glucose deprivation. Under continuous glucose supply, and upon glucose replenishment, FBP1 KO cells exhibited higher levels of TXNIP compared to wild type cells (Fig. 3 a,b&c). Consistently, lower levels of TXNIP expression were observed in FBP1 KO cells upon glucose replenishment with varying concentrations (Fig. 3 d). To show that increased TXNIP expression is a direct outcome of increased glycolysis intermediates, 2-DG was included as a positive control and elicited sharp increase in TXNIP expression (Fig. 3 d). FBP1 correlates with increased ROS accumulation, mitochondrial biomass and decreased mitochondrial inner-membrane potential MIMP In light of the observed effects on glucose catabolism and utilisation, we sought to assess the impact of FBP1 on the abundance and function of the mitochondria in addition to the related outcome of ROS accumulation. FACS analysis of DHE stained MCF-7 cells showed increased ROS accumulation in oeFBP1 vs vector control cells; consistently FBP1 KO cells exhibited significantly decreased ROS accumulation (Fig. 4 a). Using MitoTracker® Green we similarly established a positive correlation between FBP1 expression and mitochondrial biomass (Fig. 4 b), indicative of increased mitochondrial biogenesis in presence of FBP1. However, the increase in mitochondrial biomass with FBP1 expression also coincided with a diminished mitochondrial inner-membrane potential MIMP (Fig. 4 c). In line with the metabolic shift towards increased glucose catabolism and decreased glutamine consumption, we predicted that FBP1 loss would render cells independent of glutamine and more vulnerable to glucose starvation. Indeed, FBP1 absence prevented the additional ROS induction observed in glutamine deprived wild type cells (Fig. 4 d), meanwhile the FBP1 KO cells responded to glucose withdrawal by dramatically increasing their mitochondrial biomass to levels significantly higher than the wild type (Fig. 4 e). Therefore, suggesting a compensatory response to cope with glucose scarcity by increasing mitochondrial biomass to harness higher levels of energy form a dwindling level of metabolic intermediates. The increase in mitochondria with lower MIMP can explain the elevated ROS as result of a concomitant increase in the overall mitochondrial inner-membrane area, as a result of increased mitochondrial biomass, and leakiness in the electron transport chain. This also consists with the FBP1 inhibitory effects on mitophagy, since electron transport chain leaking is a hallmark of aging mitochondria. FBP1 deletion diverts ATP production from the ETC Blocking ATP-synthase with 10µM oligomycin [ 25 ] resulted in significantly smaller increase of mitochondrial polarisation in FBP1 KO MCF-7 cells compared to the wild type (Fig. 4 f). The increased polarisation reflects directly the amount of protons that would path through ATP-synthase and contribute to ATP production; hence we conclude that FBP1-deficinecy limited the reliance of MCF-7 on the electron transport chain ETC for ATP production. This consists with the increased glucose consumption, utilisation and aerobic fermentation observed in the FBP1-KO cells. FBP1-loss provides a survival advantage under extreme hypoxia The increased glucose utilisation and aerobic fermentation we observed for FBP1 KO cells consist with the conventional Warburg effect, and should coincide with decreased reliance on respiration. Hence we investigated the survival of MCF-7 FBP1-KO cells under hypoxia compared to wild type cells. Both SRB growth/survival assay (Fig. 5 a&b) and FACS analysis of PI-stained cells (Fig. 5 c) showed a statistically valid advantage for FBP1-deficeint MCF-7 cells over the wild type cells following incubations at 1% O2 saturation, SRB assays were for a time frame of 24h to 96h under hypoxia, while PI staining was performed following 48h under 1% O2 saturation. MDA-MB-231 cells acquire the capacity to degrade ectopic FBP1 in a proteasome dependent mechanism upon long-term selection To better understand the metabolic and proliferative advantages of FBP1 silencing, we aimed to determine the effects of ectopic FBP1 in the triple-negative MDA-MB-231 cells, with depleted FBP1 expression. To our surprise the stable expression of FBP1, following a minimum of 6 weeks of geneticin selection, yielded diminished levels of FBP1 expression compared to the FBP1-positive MCF-7 (Fig. 6 a). This was despite transient expression in MDA-MB-231 successfully yielding substantial levels of expression (Fig. 6 b). Quantitative PCR also showed an increase in FBP1 mRNA levels in MDA-MB-231 stable oeFBP1 cells, greater than that observed in MCF-7 oeFBP1 (Fig. 6 c). Altogether this indicated the potential of post-translational protein degradation as an underlying mechanism of the attenuated FBP1 expression in MDA-MB-231 cells. To test this possibility we resorted to pharmacological proteasome inhibition [ 26 ]. Indeed, bortezomib treatment rescued FBP1 protein expression in MDA-MB-231 cells with stable FBP1 ectopic expression while showing no effect on FBP1 in the control MDA-MB-231 cells harbouring the empty vector (Fig. 6 d). To verify the rescuing effect of proteasome inhibition on ectopic FBP1 expression in MDA-MB-231 cells we also used MG132, another more distinctive proteasome inhibitor [ 27 ], with comparable outcome to that observed with bortezomib (Fig. 6 e). We are the first to observe such degradation of FBP1 in breast cancer cells, a similar effect has been found to contribute to FBP1 ablation in hepatocellular carcinoma [ 28 ]. Upon bortezomib treatment, the rescued ectopic FBP1 expression also inhibited glucose uptake compared to the vector control cells (Fig. 6 f), similar to its identified role in MCF-7. Moreover, the transient transfection with FBP1, correlated to higher levels of expression, decreased acidification rates in MDA-MB-231 cells indicting slowed down glycolysis (Fig S4). Glutamine as an exclusive carbon source stabilizes ectopic FBP1 expression in MDA-MB-231 cells and confreres a growth disadvantage to oeFBP1 cells We next sought to assess the interplay between the ectopic FBP1 expression in MDA-MB-231 and nutrient availability in the culture medium. The post-translational proteasome-dependent degradation of FBP1 has long been described as a part of the more encompassing phenomenon of carbon catabolite inactivation in unicellular eukaryotes [ 29 ]. Glucose is the most prominent metabolite to trigger the signalling cascade, which leads to FBP1 phosphorylation, ubiquitination, and degradation both in the proteasome and the vacuole [ 30 , 31 ]. Therefore, we asked whether this mechanism is conserved in human cells. If so, the constitution and balance of carbon sources in cell culture medium should influence the observed levels of ectopic FBP1 by altering its degradation rate. First, we observed via proliferation SRB assays that the marginal amounts of stably expressed FBP1 in MDA-MB-231 were advantageous under full DMEM containing both glucose and glutamine (Fig. 7 a), as well as under high glucose concentration (75mM) with NH4Cl as the exclusive nitrogen source (Fig. 7 b), the successful utilisation of ammonia by breast cancer cells has been clearly demonstrated [ 32 ]. To our surprise however, the growth of oeFBP1 MDA-MB-231 cells was severely challenged in medium with high levels of glutamine (8mM) as the exclusive carbon and nitrogen source (Fig. 7 c). This is very intriguing in light of glutamine being a major gluconeogenic substrate. Consistently, immunoblotting showed remarkable increase in ectopic FBP1 levels under glucose depletion coupled with high glutamine concentrations (Fig. 7 d), thus indicating an attenuation of FBP1 degradation under this condition. This is to our knowledge the first reported evidence on the effect of the availability of various carbon sources on FBP1 proteasomal degradation in human cancerous cells and mammalian cells in general. Hence indicating a likely carbon catabolite inactivation phenomenon akin to that characterised in yeast. Despite its advantageous effect on proliferation, the presence of marginal ectopic FBP1 in oeFBP1 cells tangibly inhibited colony formation capacity (Fig. 7 e), consistent with the known aspects of FBP1 repression in basal-like and metastasising breast cancer. Stable and transient FBP1 expression lead to contrasting oxidative and mitochondrial outcomes in MDA-MB-231 cells Compared to its effect in MCF-7, the stable expression of FBP1 in MDA-MB-231 unexpectedly correlated to a steep decrease in ROS levels as measured using DHE (Fig S5a). However, transient expression yielding comparable levels of FBP1 to those of MCF-7 had no significant effect on ROS accumulation (Fig S5d), despite a slight trend towards increased ROS. The investigated mitochondrial markers, on the other hand, reacted similarly to the expression of FBP1 in MDA-MB-231 in a manner comparable to the observations in MCF-7. MDA-MB-231 cells with stable FBP1 expression exhibited lower mitochondrial inner-membrane polarisation and higher total mitochondrial biomass (Fig S5b&c). Transient FBP1 over-expression however yielded elevated mitochondrial polarisation (Fig S5e), hence possibly indicating an increase in respiratory activity upon FBP1 ectopic expression later followed by increased mitochondrial biogenesis. Comparing transcriptional profiles signified a wide-scale cell-cycle inhibitory effect of long term FBP1 expression in MDA-MB-231 cells Having observed that MDA-MB-231 cells adapt to FBP1 long-term expression by degrading FBP1 in the proteasome, we were intrigued to assess the shifts in transcription that can indicate the types of alterations occurring as a result of ectopically expressing FBP1 in MDA-MB-231 cells. Therefore, we used the Illumina RNA microarray system for a full transcriptome scale quantification of gene-expression of stable oeFBP1 vs vector control MDA-MB-231 cells. Following the basic quantification of fold changes in FBP1 over-expression vs vector control cells, we performed a wide analysis of the impact of FBP1 over-expression on gene-expression patterns in MDA-MB-231 including a larger pool of up-regulated (≥1.6 folds) and down-regulated (≤0.65 folds) genes (Figure S6). Using the STRING functional protein association network, two separate schemes of interaction networks between the proteins encoded by the up-regulated and down-regulated genes were made. Comparing the two interaction networks, the most noticeable difference is the clear arrangement of the down-regulated genes into an interaction-rich network (Fig S6a). At the centre of this network are proteins associated with the cell cycle progression; the vast majority are proteins essential for mitosis and cytokinesis (M-Phase) these include the centrosome proteins CENP- A,E,M,N, aurora kinase A AURK-A and its activator TPX, the kinesin family members KIFs 2C, 4A, 20A, 20B, 23 and the centrosomal protein CEP55. Besides M-phase proteins, several other genes encoding for essential cell-cycle proteins are also seen within the aforementioned interaction network. These include, the Cyclin A2 essential for the cell cycle progression G1/S and G2/M transitions through activating CDK1 (also among the down-regulated genes) and CDK2. Other down-regulated genes include the histone cluster 2 (H2AC and H2AA3) in addition to thymidilate synthetase essential for thymidine de-novo biosynthesis and the exonuclease 1 EXO1 essential for DNA-mismatch repair. In contrast with the heavy interactions observed between the down-regulated genes, the interactions among the up-regulated genes are scarce. Therefore no wider conclusions regarding the up-regulation of entire signalling pathways or cellular functions could be drawn. Immunoblotting confirmed the FBP1-associated inhibition of CENP-E In order to test the observed cell-cycle inhibition on a protein level, immunoblots of short-term transfected MDA-MB-231 cells were performed. HT-29 cells were also included to test the validity of our findings in other FBP1-deficeint cell lines of other tumor origins. Consistent with the transcriptional findings, the ectopic expression of FBP1 correlated to diminished CENP-E levels in both tested cell lines (Fig. 8 ). This finding validates the functional relevance of the cell cycle inhibition seen in the transcriptional profiling. Discussion This work aimed at investigating FBP1 as an emerging tumour suppressor in the context of breast cancer using cell lines representing the luminal and basal-like major subtypes. We studied the effects of FBP1-loss by establishing CRISPR-Cas9 knock-out of FBP1 in MCF-7 cells and characterising the resulting knock-out cell population against the otherwise genetically-identical parental MCF-7 population. Hence we are the first to share evidence from a genomic knock-out of FBP1 in cancer cells to support the tumour suppressor role ascribed to FBP1, its anti-glycolytic metabolic activity, and FBP1 repression as an important step towards aerobic glycolysis and fermentation typical to the Warburg effect [ 1 – 8 ]. Nonetheless, several particularities were identified for each cell type in regards to their response to ectopic FBP1 expression. While the additional FBP1 over-expression in MCF-7 presented a burden on growth and glucose utilisation, the endogenously FBP1-repressed MDA-MB-231 adapted to the long-term expression of FBP1 by post-translational degradation. This left a marginal amount of FBP1 upon selection of MDA-MB-231 with stable FBP1 expression. This minute amount of FBP1 expression had favourable effects for growth under glucose, and inhibited ROS accumulation. To the contrary, interventions to restore high levels of the ectopically expressed FBP1 by proteasomal inhibition or growing cells with glutamine as the restrictive carbon source, unmasked the anti-proliferative and glucose uptake inhibition associated to high levels of FBP1 as in MCF-7 cells. Similarly, the transient expression in MDA-MB-231 yielded higher levels of expression and associated to inhibition of cellular acidification, did not inhibit ROS accumulation, and exhibited comparable effects on mitochondrial variables to those observed with oeFBP1 in MCF-7. In line with earlier findings, FBP1-associated increase in mitochondrial biomass also correlated with diminished survival under hypoxia indicating increased reliance on respiration in contexts of FBP1 expression. A similar pro respiratory effect and enhanced mitochondrial activity is common to other interventions that disrupt glycolysis, as we reported very recently in regards to the effect of concentrated ascorbate on breast cancer cells [ 33 ]. Furthermore, respiratory effects of FBP1 is probably an outcome of interplay between its negative impact on glycolytic flux and its non-catalytic role as a negative co-regulator of HIF1-alpha, which has been thoroughly described in renal cancer [ 3 ]. The presence of an identical mechanism in breast cancer is highly plausible, especially that a non-catalytic role of FBP1 in preventing snail mediated EMT has already been described in breast cancer cells [ 2 ], which suggests the possibility of a non-catalytic protein-protein interaction allowing FBP1 to function as a co-regulator of gene expression. Consistent with earlier works on FBP1 in breast and renal cancers [ 2 , 3 , 34 ], we showed evidence of increased mitochondrial biomass and reliance on respiration for energy generation and survival. The links between FBP1 and mitochondrial homeostasis and function offer a potential mechanism for interventions to target tumour metabolism and abrogate the transition towards aerobic fermentation by fostering cellular respiration using FBP1 metabolite activation [ 35 ] and epigenetic interventions to prevent FBP1 repression in cancer cells and/or precancerous lesions [ 36 ]. Moreover, the FBP1-associated increase in mitochondrial mass and the reported prolonged mitochondrial retention due to inhibited mitophagy both suggest potential relevance of FBP1 and gluconeogenesis to aging and longevity. It is widely accepted that cumulative damage to the mtDNA and respiratory chain majorly contribute to aging [ 37 , 38 ]. Hence the effects of FBP1 and gluconeogenesis on the mitochondrial homeostasis of aging cells could be relevant to longevity [ 39 ]. This is relevant in light of the potential nutritional regulation of FBP1 expression, for which our preliminary results already show a promise for modulating FBP1 levels in cancer cell lines by altering nutrients availability. It did not escape our attention that the stabilisation of ectopic FBP1 under glucose restriction and glutamine abundance could constitute a hitherto unobserved form of carbon catabolite repression of FBP1 in mammalian cells, similar to the well-characterised phenomenon in yeast [ 18 , 29 ]. Proposed mechanism of dynamic FBP1 regulation light of the glucose-mediated post-translational inactivation of FBP1. Based on our observations we speculate that epigenetic silencing of FBP1 in cancer cells is incomplete and not sufficient for the metabolic adjustment driving cancer metabolism. Thus, silencing of FBP1 is complemented by post-translational repression. Vice versa, glucose withdrawal allows for the restoration of FBP1 expression in a self-sustaining cycle: diminished glucose levels alleviate the proteasomal degradation and the increased FBP1 level further inhibits glucose uptake and glycolysis and therefore keeps the glucose-mediated FBP1 post-translational inactivation at bay. Since we reached these findings in cell culture by applying extreme and physiologically irrelevant conditions of glucose deprivation it remains to be seen how this mechanism applies in-vivo both in cancer cells, precancerous lesions, and under normal physiology in normal cells. With that said and considering the newly described relevance of FBP1 to transcriptional control, the above described mechanisms of FBP1 restoration could open a door for the metabolic rewiring of cancer cells diverting them away from the Warburg model and limiting aggressiveness. Uncovering the in-vivo physiology of FBP1 post-translational control would be very relevant to both cancer and metabolic disease since it would mean that dietary and nutritional intervention can contribute to the long term sustenance or ablation of FBP1 expression. Furthermore, the dynamic effect of nutrient availability on FBP1 expression in cancer cells makes space for speculation regarding a plausible mechanism of the robust anti-cancer effect attributed to metformin in wide population studies showing diminished cancer risk in type-II diabetics on metformin [ 40 ]. In this mechanism the glucose lowering effect of metformin, especially via blocking the hepatic gluconeogenesis [ 41 ], would have a stabilising effect on FBP1 expression in the periphery and preserve its quasi tumour suppressor role. We are therefore focused on further identifying the molecular mechanism, magnitude, and versatility of this effect. Conclusions In this study we provided the first genomic-based evidence on the relevance of FBP1 to the emergence of Warburg effect. We also demonstrated for the first time the capability of particular breast cancer cells to degrade FBP1 as a response to its enforced ectopic expression. Moreover, we also analysed the effect of nutrient availability in the culture medium on FBP1 mediated effects on cellular proliferation and survival. Our current and future work will focus on identifying the exact mechanism behind FBP1 post-translational regulation in cancer cells in the hope of identifying physiologically relevant mechanisms contributing to FBP1 ablation in cancer initiation and progression, in addition to metabolic diseases. Methods Cell culture: the cell-lines MCF-7, MDA-MB-231 (ATCC) were incubated at 37° and 5% CO2. All passaging, cultivation, seeding and treatments were performed in Dublecco’s modified eagle medium DMEM (Gibco, Germany) for details refer to Supp. Methods I . MCF-7 and MDA-MB-231 cells (ATCC) were obtained in 2012, preserved in liquid nitrogen and utilized for experiments in passage between 15 and 30. Cells were also tested for mycoplasma. Further details in Supp. Methods I . Cells were treated with various media conditions as indicated, fresh DMEM was prepared from scratch with glucose, glutamine, and NH4Cl added freshly to reach the indicated concentrations. For proteasome inhibition, bortezomib (Selleckchem®) and MG132 (Sigma-Aldrich®) were used. Molecular cloning and construction of plasmids To establish ectopic expression of FBP1 in the tested cell lines, new plasmids were constructed with FBP1 variants expressed under a constitutive mammalian promoter. For this purpose I started with the commercially available pcDNA3.1(-) vector. (For the detailed method please refer to the Supp. Methods II ) Transfection of cell lines and establishing stable over-expressions and deletions Lipid-based transfection was used, Lipofectamin TM 3000 (Thermo Fisher®, Waltham MA), for introducing the FBP1 over-expression or CRISPR-Cas9 deletion vectors into the cell lines. The transfections were performed using the protocols provided with the transfection reagents. (The detailed methods of trnasfection and establishing the stable cell lineages in the Supp. Methods III ) Protein extraction for immunoblotting To extract total proteins from cells, 3*10 5 to 5*10 5 cells were seeded, following 24 to 48 hours of incubation cells were subjected to the desired treatment or medium conditions and then lysed in 6 M urea buffer containing the following protease inhibitors: (NaF, PMSF, Pepstatin, Aprotenine and NaVO 4 ). To lyse the cells, medium was aspirated, and 120 to 180 µl ice-cold 6 M Urea buffer were pipetted directly onto the cells. Subsequently, the cell culture plates were promptly placed on ice and then vortexed to ensure full homogenization in the Urea buffer. Afterwards, lysates were collected in Eppendorf tubes and then spun down at 13000 g for 15 minutes to get rid of the DNA. Lysates were subsequently stored at -20°C. Determining total protein concentrations Total protein concentrations in the lysates were determined using Bradford reaction. 10 µl of each lysates were mixed with 990 µl of Bradford reagent (Sigma-Aldrich) in Eppendorf tubes. Samples were then mixed and incubated for 5 minutes in the dark. Subsequently 3x300 µl of each sample were transferred into 96 well-plates and measured using the Tecan Ultra (Tecan, Germany) reader at 595 nm. SDS-PAGE and immunoblotting Proteins in denatured lysates were resolved on 10% polyacrylamide gel (SDS-PAGE) as described in (Laemmli, 1970)[ 42 ]. Afterwards, resolved proteins were blotted (transferred) from the resolving SDS-PAGE gel onto a PVDF membrane. Semi-dry protein transfer was used with anode and cathode buffer prepared as detailed in the above material section. Subsequently, membranes were stained with ponceau S (5% ponceau S) and then washed in TBS-tween 1% (v/v) buffer and blocked in a 5% BSA solution in TBS-tween buffer for 1 hour, and then incubated with 1:1000 solution of one of the used primary antibodies. After the primary anti-body incubation, membranes were washed 3 times for 5 minutes each in TBS-tween 1 buffer and subsequently incubated in 1:5000 HRP-fused anti rabbit or anti mouse secondary (IgG) anti-body solutions for 1 hour. Finally, membranes were washed 3 x 5 minutes and developed in Western Lightning Plus-ECL (Perkin-Elmer, Germany). Signals were detected using the Fujifilm LAS-3000 imaging system and the AIDA software for image acquisition. Quantification of western-blot signals the intensities of the western-blot bands of target proteins were quantified using the Image-J histogram quantification tool. The intensity of the target protein signals was adjusted relative to the corresponding loading-control (beta-actin) bands. SRB Survival and growth assays The total-protein based SRB colourimetric assay was used to assess cell survival and growth of cells with various FBP1 contexts under the indicated media conditions/treatments. The utilised SRB-assay protocol was derived from Vichai and Kirtikara 2006 [ 43 ]. For the detailed SRB method refer to the Supp. Methods IV ) FACS analysis Fluorescence activated cell sorting FACS analysis was used to measure a variety of metabolic and viability markers in the cells. Cells were seeded in 12 well plates at a density of 50,000 cells/well in 1 ml full DMEM/well and incubated over-night. On the following day medium was aspirated, and cells were treated as indicated for each experiment). Following treatment, cells were incubated with the fluorescent probes) then analysed using FACS Guava (Merck-Millipore, UK). The following probes were used; 2-NBDG for glucose uptake[ 44 ], DHE for intracellular ROS accomulation [ 45 ], MitTracker Green for mitochondrial mass, and JC-1 for mitochondrial inner-membrane potential. (Detailed methods and mechanisms for each fluorescent probe are listed in the Supp. Methods V.) Liquid chromatography-mass spectrometry based metabolite quantification: Intracellular metabolites were extracted and quantified using an LC-MS based method as previously described in [ 46 ]. Details in Supp. Methods VI . Extraction of RNA from cultured cells Cells were seeded in full DMEM in six-well plates at a density of 2x10 5 cells/well. After 1 day cells were treated, or transfected as indicated, and after the indicated duration of treatment mRNA was extracted using the following triazole/chloroform method. (For the detailed methods of the mRNA extraction refer to the Supp. Methods VII .) Complementary DNA (cDNA) synthesis The synthesis of cDNA from the isolated RNA was carried out using the ProtoScript® First Strand Synthesis kit from NEB®. The cDNA was synthesised using the protocol provided with the kit. To ensure that the mRNA is exclusively reverse-trscribed without other RNA types in the mixture, the reverse transcription was performed using poly-t primers that anneal specifically to the poly-A tails of the mRNA transcripts. Real-time quantitative PCR rt-qPCR For the quantitative PCR the LightCycler® Sybr Green (Roche®) reaction mix was utilized. The reactions were prepared according to the following protocol: The following master-mix was prepared for each primer pair (target gene) to be tested. Quantities are giver for 1 reaction: Cybr Green®: 2.5 µl Primer Mix: 1 µl Nuclease free water: 0.5 ml Pipetted onto 1 µl of cDNA (concnetration≈30 ng/µl) The tested cDNAs were pipetted in Microplate 96 LP (Analytik Jena AG) compatible to the qTOWER real-time PCR thermal cycler (Analytik Jena AG). 4 µl of the master-mix were pipetted in triplets on each type of the tested cDNAs. Subsequently, the plates were fed into the qTower real-time PCR thermal cycler, where the reactions occurred and the results were obtained. Quantitative interpretation of the qPCR data The mean values of the yielded CT of each triplet or reactions were calculated, including the mean-values of each tested cDNA with the reference genes. Then using these mean values of the CT of each target and reference genes, relative expression of the target genes was compared for the different cDNAs (treated vs non-treated or transfected vs empty vector) using the ∆∆CT equation to yield the relative expression values: ∆Ct=Ct (target gene) -Ct (reference gene) for a given sample. ∆∆Ct=∆Ct (treated sample) -∆Ct(control sample) Relative expression (Fold change)=-2 ∆∆Ct Transcriptional profiling of MDA-MB-231 cells RNA was extracted from 500.000 cells. RNA concentrations were adjusted to 100ng/µl and samples were sent to collaborators in the Functional Genome Analysis Division in DKFZ (Lab of Professor Jörg Hoheisel), were they were analysed using the Illumina RNA microarray system. The utilised method was described in previously published research from the group [ 47 ]and is summarised below: RNA-integrity of the samples was verified using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto). The analysis of the total RNA in the samples was performed using Sentrix Human-6v3 Whole Genome Expression BeadChips (Sentrix Human WG-6; Illumina). Following hybridisation to the chips according to the manufacturer’s instructions, the arrays were scanned with a BeadArray Reader (Illumina). Colony forming assay Cells with different FBP1 expression were seeded in 6 well plates at the extra-low density of 300 cells/well in 2 ml full DMEM, refreshed every 7 days. After 2 weeks (MDA-MB-231) or 3 weeks (MCF-7) of incubation colonies were fixed and stained using a PBS solution containing 0.021% (v/v) formaldehyde and 0.5% (w/v) crystal violet. Declarations Competing interests The authors declare no conflict of interests. Authors’ contributions Concept and experimental design A.G. and S.W.; Experimentation; A.G. and B.T.; Methodology A.G. and S.W.; Funding and Supervision S.W.; Data analysis and interpretation A.G. and S.W.; Data presentation and figure design A.G. and S.W.; drafting the manuscript A.G. and S.W. All authors read and approved the manuscript before submission. Funding A.G. received a DAAD fellowship to pursue his PhD in the Wölfl Lab, parts of this study were also supported by BMBF funding with the following grants FKZ 01EK1612C and FKZ 031A303E. We would also like to acknowledge the financial support from the DFG and Heidelberg University within the Open Access Publishing. Acknowledgements We thank Esther Zaal and Celia Berkers (Utrecht University) for their support with the metabolite quantification using HPLC-MS in addition to Andrea Bauer and Jörg Hoheisel (DKFZ) for their support with preliminary transcriptional profiling. Ethical approval and consent to participate and consent for publication We conducted our study in standard breast cancer cell lines with no patient material or animals involved. Hence no ethical approval or consents were required. Availability of data and material All data and material connected to this work are available and can be provided upon request. References Chen M, Zhang J, Li N, Qian Z, Zhu M, Li Q, Zheng J, Wang X, Shi G: Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer . PLoS One 2011, 6 (10):e25564. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, Lin Y, Yao J, Shi J, Kang T et al : Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer . Cancer Cell 2013, 23 (3):316–331. Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I et al : Fructose-1,6-bisphosphatase opposes renal carcinoma progression . Nature 2014, 513 (7517):251–255. Zhang J, Wang J, Xing H, Li Q, Zhao Q, Li J: Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells . Mol Cell Biochem 2016, 411 (1-2):331–340. Zhu Y, Shi M, Chen H, Gu J, Zhang J, Shen B, Deng X, Xie J, Zhan X, Peng C: NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells . Oncotarget 2015, 6 (25):21443–21451. Sheng H, Ying L, Zheng L, Zhang D, Zhu C, Wu J, Feng J, Su D: Down Expression of FBP1 Is a Negative Prognostic Factor for Non-Small-Cell Lung Cancer . Cancer Invest 2015, 33 (5):197–204. Li J, Wang Y, Li QG, Xue JJ, Wang Z, Yuan X, Tong JD, Xu LC: Downregulation of FBP1 Promotes Tumor Metastasis and Indicates Poor Prognosis in Gastric Cancer via Regulating Epithelial-Mesenchymal Transition . PLoS One 2016, 11 (12):e0167857. Hirata H, Sugimachi K, Komatsu H, Ueda M, Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y et al : Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma . Cancer Res 2016, 76 (11):3265–3276. Li H, Li M, Pang Y, Liu F, Sheng D, Cheng X: Fructose1,6bisphosphatase1 decrease may promote carcinogenesis and chemoresistance in cervical cancer . Mol Med Rep 2017, 16 (6):8563–8571. Cheng P, Wang Z, Hu G, Huang Q, Han M, Huang J: A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy . Oncotarget 2017, 8 (61):103327–103339. Wang H, La Russa M, Qi LS: CRISPR/Cas9 in Genome Editing and Beyond . Annu Rev Biochem 2016, 85 :227–264. Doudna JA, Charpentier E: Genome editing. The new frontier of genome engineering with CRISPR-Cas9 . Science 2014, 346 (6213):1258096. Moore JD: The impact of CRISPR-Cas9 on target identification and validation . Drug Discov Today 2015, 20 (4):450–457. Lu Q, Livi GP, Modha S, Yusa K, Macarron R, Dow DJ: Applications of CRISPR genome editing technology in drug target identification and validation . Expert Opin Drug Discov 2017, 12 (6):541–552. Ghanem A, Kitanovic A, Holzwarth J, Wolfl S: Mutational analysis of fructose-1,6-bis-phosphatase FBP1 indicates partially independent functions in gluconeogenesis and sensitivity to genotoxic stress . Microb Cell 2017, 4 (2):52–63. Kitanovic A, Wolfl S: Fructose-1,6-bisphosphatase mediates cellular responses to DNA damage and aging in Saccharomyces cerevisiae . Mutat Res 2006, 594 (1-2):135–147. Muir A, Danai LV, Vander Heiden MG: Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies . Dis Model Mech 2018, 11 (8). Hammerle M, Bauer J, Rose M, Szallies A, Thumm M, Dusterhus S, Mecke D, Entian KD, Wolf DH: Proteins of newly isolated mutants and the amino-terminal proline are essential for ubiquitin-proteasome-catalyzed catabolite degradation of fructose-1,6-bisphosphatase of Saccharomyces cerevisiae . J Biol Chem 1998, 273 (39):25000–25005. Kuehne A, Emmert H, Soehle J, Winnefeld M, Fischer F, Wenck H, Gallinat S, Terstegen L, Lucius R, Hildebrand J et al : Acute Activation of Oxidative Pentose Phosphate Pathway as First-Line Response to Oxidative Stress in Human Skin Cells . Mol Cell 2015, 59 (3):359–371. Ralser M, Wamelink MM, Kowald A, Gerisch B, Heeren G, Struys EA, Klipp E, Jakobs C, Breitenbach M, Lehrach H et al : Dynamic rerouting of the carbohydrate flux is key to counteracting oxidative stress . J Biol 2007, 6 (4):10. Dick TP, Ralser M: Metabolic Remodeling in Times of Stress : Who Shoots Faster than His Shadow? Mol Cell 2015, 59 (4):519-521. Dombrauckas JD, Santarsiero BD, Mesecar AD: Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis . Biochemistry 2005, 44 (27):9417–9429. Dayton TL, Jacks T, Vander Heiden MG: PKM2, cancer metabolism, and the road ahead . EMBO Rep 2016, 17 (12):1721–1730. Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen CH, Wen J, Asara J, McGraw TE et al : AMPK - dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1 . Mol Cell 2013, 49 (6):1167-1175. Salomon AR, Voehringer DW, Herzenberg LA, Khosla C: Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase . Proc Natl Acad Sci U S A 2000, 97 (26):14766–14771. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, Neslund-Dudas C, Mitra B, Dou QP: From bortezomib to other inhibitors of the proteasome and beyond . Curr Pharm Des 2013, 19 (22):4025–4038. Guo N, Peng Z: MG132, a proteasome inhibitor, induces apoptosis in tumor cells . Asia Pac J Clin Oncol 2013, 9 (1):6–11. Jin X, Pan Y, Wang L, Zhang L, Ravichandran R, Potts PR, Jiang J, Wu H, Huang H: MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation . Oncogenesis 2017, 6 (4):e312. Chen SJ, Wu X, Wadas B, Oh JH, Varshavsky A: An N-end rule pathway that recognizes proline and destroys gluconeogenic enzymes . Science 2017, 355 (6323). Schork SM, Bee G, Thumm M, Wolf DH: Catabolite inactivation of fructose-1,6-bisphosphatase in yeast is mediated by the proteasome . FEBS Lett 1994, 349 (2):270–274. Horak J, Regelmann J, Wolf DH: Two distinct proteolytic systems responsible for glucose-induced degradation of fructose-1,6-bisphosphatase and the Gal2p transporter in the yeast Saccharomyces cerevisiae share the same protein components of the glucose signaling pathway . J Biol Chem 2002, 277 (10):8248–8254. Spinelli JB, Yoon H, Ringel AE, Jeanfavre S, Clish CB, Haigis MC: Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass . Science 2017, 358 (6365):941–946. Ghanem A, Melzer AM, Zaal E, Neises L, Baltissen D, Matar O, Glennemeier-Marke H, Almouhanna F, Theobald J, Abu El Maaty MA et al : Ascorbate kills breast cancer cells by rewiring metabolism via redox imbalance and energy crisis . Free Radic Biol Med 2021, 163 :196-209. Shi L, He C, Li Z, Wang Z, Zhang Q: FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1alpha . Neoplasma 2017, 64 (4):535–542. Icard P, Fournel L, Coquerel A, Gligorov J, Alifano M, Lincet H: Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy . Cancer Cell Int 2018, 18 :175. Yang J, Jin X, Yan Y, Shao Y, Pan Y, Roberts LR, Zhang J, Huang H, Jiang J: Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression . Sci Rep 2017, 7 :43864. Sun N, Youle RJ, Finkel T: The Mitochondrial Basis of Aging . Mol Cell 2016, 61 (5):654–666. Bratic A, Larsson NG: The role of mitochondria in aging . J Clin Invest 2013, 123 (3):951–957. Liu Y, Jiang Y, Wang N, Jin Q, Ji F, Zhong C, Zhang Z, Yang J, Ye X, Chen T: Invalidation of mitophagy by FBP1-mediated repression promotes apoptosis in breast cancer . Tumour Biol 2017, 39 (6):1010428317708779. Vancura A, Bu P, Bhagwat M, Zeng J, Vancurova I: Metformin as an Anticancer Agent . Trends Pharmacol Sci 2018, 39 (10):867–878. Hunter RW, Hughey CC, Lantier L, Sundelin EI, Peggie M, Zeqiraj E, Sicheri F, Jessen N, Wasserman DH, Sakamoto K: Metformin reduces liver glucose production by inhibition of fructose - 1 - 6 - bisphosphatase . Nat Med 2018, 24 (9):1395-1406. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4 . Nature 1970, 227 (5259):680–685. Vichai V, Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening . Nat Protoc 2006, 1 (3):1112–1116. Zou C, Wang Y, Shen Z: 2-NBDG as a fluorescent indicator for direct glucose uptake measurement . J Biochem Biophys Methods 2005, 64 (3):207–215. Zhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, Vasquez-Vivar J, Kalyanaraman B: Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide . Free Radic Biol Med 2003, 34 (11):1359–1368. Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR: Bortezomib resistance in multiple myeloma is associated with increased serine synthesis . Cancer Metab 2017, 5 :7. Bauer AS, Nazarov PV, Giese NA, Beghelli S, Heller A, Greenhalf W, Costello E, Muller A, Bier M, Strobel O et al : Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer . Int J Cancer 2018, 142 (5):1010–1021. Perelman A, Wachtel C, Cohen M, Haupt S, Shapiro H, Tzur A: JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry . Cell Death Dis 2012, 3 :e430. Scheme Schemes 1 and 2 are available in the Supplemental Files section. Supplementary Files GraphicalAbstract.png SupplementaryMaterials.docx Scheme1.png Scheme2.png Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1030616","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research","associatedPublications":[],"authors":[{"id":62881386,"identity":"767e063b-80d5-4441-bed0-45d7716e40d1","order_by":0,"name":"Ali Ghanem","email":"","orcid":"","institution":"Heidelberg University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ali","middleName":"","lastName":"Ghanem","suffix":""},{"id":62881387,"identity":"8466ae8e-fb1b-4980-a8a5-f82627156ccf","order_by":1,"name":"Boilinh Troung","email":"","orcid":"","institution":"Heidelberg University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Boilinh","middleName":"","lastName":"Troung","suffix":""},{"id":62881388,"identity":"3376402a-8b7d-428b-9b4f-034454060fb4","order_by":2,"name":"Stefan Wölfl","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAq0lEQVRIiWNgGAWjYFAC5oYPDyoYGNgYeBgkgCQxgLFxRsIZkrUktoEYxGoxON7Y2JA473AeHwPvwRsMZTZEaDlzEKhl2+FiNga+ZAuGc2mEtZjdSGx/ANSS2Cb/xkyCse0wUVqAtswBamHgAWn5T6yWBriWA4S12IP8knAsHaTF2CLhXDJhLZLtzQcbPtRYJ85v4DG88aHMjrAWVJBAqoZRMApGwSgYBdgBAEnnO1T0rDbVAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-9977-174X","institution":"Institute of Pharmacy and Molecular Biotechnology, Heidelberg University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Stefan","middleName":"","lastName":"Wölfl","suffix":""}],"badges":[],"createdAt":"2021-10-29 09:09:51","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1030616/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1030616/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":15593490,"identity":"17721de5-425c-4a98-adab-f68679017a6b","added_by":"auto","created_at":"2021-11-16 15:12:48","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":421874,"visible":true,"origin":"","legend":"FBP1 effects on proliferation and colony formation of MCF-7 cells\na) SRB proliferation assays of MCF-7 oeFBP1 vs vector control cells (left) and of the FBP1-/- vs wild-type (right). b) SRB proliferation assays of MCF-7 cells with DMEM medium containing various glucose concentrations (20mM, 2mM and 0mM). a\u0026b) Data points show mean-values ±SD (n= 5 or 6). c) Colony formation assay of MCF-7 cells in full DMEM (3 weeks incubation in full DMEM, weekly replaced). ","description":"","filename":"fig1.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/eda2fb67cfa22d052e8d43ed.png"},{"id":15594076,"identity":"10f6083b-cbc7-4054-9987-7f6523be07ae","added_by":"auto","created_at":"2021-11-16 15:15:49","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":148129,"visible":true,"origin":"","legend":"The over-expression of FBP1 slows down glucose uptake, while the deletion thereof induces glycolytic flux in MCF-7 cells. a) Glucose uptake in full DMEM (20mM glucose, 2mM glutamine) measured by FACS analysis of MCF-7 cells incubated with 2-NBDG for 4 hours. 5000 cells were analyzed; featured are the mean values ±SD (n≥4). b) Glucose uptake of MCF-7 cells in glutamine-depleted DMEM and following depletion and replenishment of Glucose. Glucose was withdrawn for 16 hours, followed by 4 hours of glucose replenishment at 20mM Glucose (Glu-/+) accompanied by 2-NBDG. Glutamine was withdrawn for a total of 20 hours (Gln-), including the last 4 hours of incubation with 2-NBDG.\nc to f) HPLC-MS quantification of intracellular metabolites in FBP1-/- MCF-7 cells relative to wild-type MCF7 cells; c) glycolytic intermediates, d) pentose phosphate pathway e) TCA cycle f) amino-acids exhibiting statistically significant shift in their abundance in FBP1 K.O vs wild type.\ng) Significantly altered extracellular metabolite abundances in the cell culture medium. The colours in the heat map indicate the relative abundance of the metabolites (in binary log) in FBP1 KO cells relative to the parental MCF-7 wild type population. Statistical significance is indicated with asterisks to the right. \n","description":"","filename":"fig2.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/8119997f6b8cbc0e491243fa.png"},{"id":15593491,"identity":"e6437056-b83f-404a-a13f-4590e65d4557","added_by":"auto","created_at":"2021-11-16 15:12:48","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":160004,"visible":true,"origin":"","legend":"Western-blots showing the FBP1-related alterations in glucose sensitivity and response to glucose starvation in MCF-7 cells. a) Full glucose deprivation 0mM glucose for 24 hours. b) Glucose replenished condition; 20 hours of glucose starvation followed by 4 hours of glucose replenishment 20mM. c) Full medium 20mM glucose. All western-blots feature biologically independent, simultaneously treated triplets of wild type and FBP1-knockout MCF7. (The bar-blots below the western-blots in a, b and c indicate semi-quantification of the FBP1 and TXNIP signals normalized to the respective housekeeping signals. The featured values represent mean ±SD, n=3). \nd) The effects of various glucose starvation and replenishment conditions (as indicated in the charts above the blots) in addition to 2-DG as a positive control for glycolytic metabolite accomulation and TXNIP induction. \n\n","description":"","filename":"fig3.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/13b2bd1ac0a9c3fcfdb22560.png"},{"id":15593496,"identity":"14bde5f3-a6db-4464-885e-7767bd111d98","added_by":"auto","created_at":"2021-11-16 15:12:49","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":105390,"visible":true,"origin":"","legend":"FBP1 increases oxidative stress and mitochondrial biomass in MCF-7 cells. \na) ROS accumulation in MCF-7 cells cultivated in full DMEM measured using DHE fluorescence. b) Mitochondrial mass in MCF-7 cells in full DMEM measured using the MitoTracker® Green probe. \nc) Mitochondrial inner-membrane potential MIMP measured using JC-1 in MCF-7 cells cultivated in full DMEM. In a, b, and c cells were analysed using FACS analysis, the bar-plots feature the fluorescence mean-values ±SD of at least 4 completely independent replicates of 5000 cells each normalized to the non-treated wild-type or control vector cells. d) ROS accumulation in MCF-7 cells deprived of glucose or glutamine compared to full medium. DHE-labelled cells were analysed using FACS (5000 cells measured). The featured values represent mean ±SD, n=3. e) Mitochondrial biomass in MCF-7 cells deprived of glucose or glutamine compared to full medium. MitoTracker Green labelled cells were measured using FACS, the bar-plots feature the mean-values of at least 3 independent replicates and the error bars represent the standard deviation. f) Relative mitochondrial inner-membrane potential measured following 24 hours of oligomycin (10µM) treatment in MCF-7 cells WT vs FBP1-/-. Depicted are mean-values of three treatments normalized to the non-treated \n\n","description":"","filename":"fig4.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/248aae14e30b8e3ed8d706ff.png"},{"id":15594663,"identity":"e46b5d57-d75d-4bd3-a42f-c535a4d9bf2b","added_by":"auto","created_at":"2021-11-16 15:18:49","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":137468,"visible":true,"origin":"","legend":"FBP1 knockout improves MCF-7 survival under hypoxic conditions. \na\u0026b) SRB proliferation/survival assays of MCF-7 cells FBP1 K.O. vs WT under normoxic and hypoxic (1% oxygen saturation) conditions, respectively. c) Propedium iodide PI staining of dead-cell fractions upon 48-hour of incubation at 1% oxygen saturation. Featured are the percentages of the PI-positive fractions analysed using FACS (5000 cells/sample), mean values±SD, n=3.\n\n","description":"","filename":"fig5.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/cd0c8686b60f91a0dadc84b0.png"},{"id":15593500,"identity":"c891c6dc-0386-4afa-8064-85547c513c56","added_by":"auto","created_at":"2021-11-16 15:12:49","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":267239,"visible":true,"origin":"","legend":"MDA-MB-231 cells degrade the ectopically expressed FBP1. a) Western-blot showing the levels of over-expressed FBP1 in MDA-MB-231 cells compared to those of MCF7 cells. Actin is used as loading control. b) Western-blot showing the expression of FBP1 in MDA-MB-231 following 24h and 96h of transient transfection. Actin was used as a loading control. c) qPCR showing the levels of FBP1 transcripts in MCF-7 and MDA-MB-231 oeFBP1 cells compared to cells carrying the empty vector. Rpl30 was used as a housekeeping reference gene. d) Western-blot featuring the levels of FBP1 in bortezobmib-treated (48 hours) MDA-MB-231 cells oeFBP1 vs empty vector. Non-treated MCF-7 cells (oeFBP1, vector control) were used as a positive reference for FBP1 expression. Vinculin and actin are used as loading controls. d) Western-blot showing FBP1 levels in MDA-MB-231 cells (oeFBP1 vs vector control) e) Western-blot showing FBP1 levels in MDA-MB-231 cells (oeFBP1, vector control) following 24 hours of bortezomib 50nM (BZ) or MG132 0.5µM (MG) treatments. Actin was used as a loading control. f) Glucose uptake in stably transfected MDA-MB-231 cells (oeFBP1 vs vector). Glucose uptake was compared for non-treated and 24-h 25 nM bortezomib (BZ) treated cells. Glucose uptake was measured using FACS analysis of cells pre-incubated with full DMEM with 2-NBDG. 5000 cells were analysed per replicate, the values represent the mean±SD, n=3.","description":"","filename":"fig6.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/3959a433c52427c7e960444c.png"},{"id":15593501,"identity":"d83d4d13-82a1-41d6-b1b0-024a1ac6e39f","added_by":"auto","created_at":"2021-11-16 15:12:49","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":468986,"visible":true,"origin":"","legend":"the effects of stable FBP1 expression on MDA-MB-231 cells. \nA,b\u0026c) SRB proliferation assays of MDA-MB-231 cells oeFBP1 vs vector in various media conditions a) full DMEM with 25mM glucose and 2mM glutamine, b) high glucose 75mM with NH4Cl 1mM as an exclusive nitrogen source c) high glutamine 8mM as the only carbon and nitrogen source. a,b and c) data points represent mean-values ±SD (n=6). Basal ROS accumulation in MDA-MB-231 cells (oeFBP1 vs vector) as measured using FACS analysis of DHE stained cells. 5000 cells of 3 biologically independent replicates were analysed (N=3, error-bar: SD). \nd) Western-blot of MDA-MB-231 empty vector and oeFBP1, featuring the regulation of ectopic FBP1 protein levels by variant media conditions. Vinculin expression was used as a loading control. Below is a quantification of FBP1 signal intensities, adjusted to vinculin intensity. Shown are the adjusted FBP1 band-intensity relative to that of the oeFBP1 cells in full DMEM (25mM glucose and 2mM glutamine). \ne) Colony formation assay of stably transfected MDA-MB-231 cells oeFBP1 vs vector. 200 cells/well were seeded and incubated in full DMEM for two weeks (medium refreshed after 1 week incubation) and then fixed and stained with PFA/crystal violet solution. \n","description":"","filename":"fig7.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/27682dfc8196afcf009b1633.png"},{"id":15594876,"identity":"1df6f2b9-bb41-4fcb-951d-ee0543aef238","added_by":"auto","created_at":"2021-11-16 15:21:49","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":106803,"visible":true,"origin":"","legend":"Western-blots showing the levels of transient over-expression of FBP1 4, 24 and 96 hours post-transfection and the concomitant levels of CENP-E. Left: MDA-MB-231, Right: HT-29. (The bar-blots below the western-blots indicate semi-quantification of the FBP1 and CENP-E signals normalized to the respective housekeeping signals).\n \n","description":"","filename":"fig8.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/24fe305fb3813e1c7a607295.png"},{"id":18563701,"identity":"0dd2060a-d4b5-49ad-bc77-77563818dbdb","added_by":"auto","created_at":"2022-02-24 12:56:10","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3473644,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/e8c9ecd9-6a8f-4c5a-9981-701cf6a6b79e.pdf"},{"id":15594875,"identity":"db5c37d4-fa14-491b-baad-ed5372d1909b","added_by":"auto","created_at":"2021-11-16 15:21:49","extension":"png","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":182558,"visible":true,"origin":"","legend":"","description":"","filename":"GraphicalAbstract.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/44d37bf066dff08fe2e22c70.png"},{"id":15593498,"identity":"527591c5-533c-42f8-9ab7-981029eeedd5","added_by":"auto","created_at":"2021-11-16 15:12:49","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":5893507,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryMaterials.docx","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/9b14a6e4bd7f07e0182790f2.docx"},{"id":15593492,"identity":"831fad84-48f3-4bb2-942d-1c33d49f5523","added_by":"auto","created_at":"2021-11-16 15:12:48","extension":"png","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":182558,"visible":true,"origin":"","legend":"","description":"","filename":"Scheme1.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/9a752d720a1e072f5a222dd7.png"},{"id":15594078,"identity":"58bbcc8e-8568-4929-91fa-417d8268c644","added_by":"auto","created_at":"2021-11-16 15:15:49","extension":"png","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":138427,"visible":true,"origin":"","legend":"","description":"","filename":"Scheme2.png","url":"https://assets-eu.researchsquare.com/files/rs-1030616/v1/3137896136fb3a8ccd0e68e7.png"}],"financialInterests":"","formattedTitle":"\u003cp\u003eGenetic Manipulation of FBP1 Expression in Breast Cancer Cells Reveals the Potential of FBP1 to Disrupt The Warburg Effect, and Nutrient Mediated Adaptive Post-Translational Regulation of FBP1 Protein Levels.\u003c/p\u003e","fulltext":[{"header":"Summary/ Highlights","content":"\u003cul\u003e\n \u003cli\u003eFBP1 is a quasi-tumor suppressor, whose levels diminish with cancer initiation and/or progression. \u003c/li\u003e\n \u003cli\u003eFBP1 expression inhibits glucose uptake and metabolism and promotes respiration and mitochondrial activity. \u003c/li\u003e\n \u003cli\u003eThe loss of FBP1 fosters the Warburg effect. \u003c/li\u003e\n \u003cli\u003eWe describe an additional layer of FBP1 depletion on the post translational level. \u003c/li\u003e\n \u003cli\u003eCells with diminished FBP1 use the proteasome system to degrade the FBP1 protein; this is reversible and happens only in the presence of glucose.\u003c/li\u003e\n \u003cli\u003eThis mechanism is reminiscent of the FBP1 regulation in yeast, required for rapid adjustment to nutrient availability and growth conditions. \u003c/li\u003e\n \u003cli\u003eThe glucose-mediated proteasomal degradation of FBP1 allows a self-propagating cycle of increased glucose uptake leading to further repression of FBP1, which in turn allows for increased glucose uptake. \u003c/li\u003e\n \u003cli\u003eConsistently, higher levels of FBP1 correlated with broad inhibition of cell cycle factors especially belonging to the G2/M phase. \u003c/li\u003e\n\u003c/ul\u003e"},{"header":"Introduction","content":"\u003cp\u003eRecent years have seen a surge in research exploring the relevance of gluconeogenesis and the key enzyme fructose-1,6-bis-phosphatase FBP1 in cancer contexts [\u003cspan additionalcitationids=\"CR2 CR3 CR4\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. The epigenetic silencing of FBP1 has been observed in several types of tumours and linked to poorer prognoses [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan additionalcitationids=\"CR6 CR7 CR8\" citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. For many cancers, the loss of FBP1 has been described as an advantageous event in the metabolic rewiring towards aerobic glycolysis. However, some cancer types show ambivalence in their FBP1 expression, with FBP1 expression maintained in less critical lesions and FBP1-loss having a poor prognostic relevance[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Breast tumours with better survival rates show positive FBP1 expression, while the more advanced forms of basal-like, triple-negative and metastatic breast cancer lack FBP1 expression. [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThis heterogeneity of breast cancers in regard to FBP1 expression makes breast cancer cells an apt model to further investigate the effects and regulation of FBP1 in contexts of cancer. To address this issue, we established stable over-expressions and a CRISPR-Cas9 knock-out of FBP1 in cultured breast cancer cell lines representing the two major subtypes; luminal (MCF-7) and basal-like (MDA-MB-231) (Fig S1) to investigate the impact of FBP1 in breast cancer with emphasis on the particularities of the two cellular environments. This was achieved by characterising the proliferative, metabolic, and oxidative effects of stable FBP1 over-expression and knock-out.\u003c/p\u003e \u003cp\u003eWe demonstrate evidence of non-genomic FBP1-repression promoting further metabolic reprogramming to foster the Warburg effect, including increased aerobic fermentation, and glucose catabolism through both the glycolytic and pentose phosphate pathways, in addition to an increase in the levels of particular amino acids derived from both pathways.\u003c/p\u003e \u003cp\u003eOur findings signify clear distinctions between the two cell types in their reaction to ectopic FBP1. Our findings demonstrate an important role for post-translational regulation of FBP1 levels in breast cancer cells by protein degradation, and the modulation of FBP1 levels based on nutrient availability in the medium.\u003c/p\u003e \u003cp\u003eThe emergence of CRSPR-Cas9 as a highly malleable and adaptable tool has made precise gene editing more feasible than ever before [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e], and opened the avenue for new genetic screens and precise genomic target validation and confirmation of findings based on non-genomic interference studies (i.e. siRNA) [\u003cspan additionalcitationids=\"CR13\" citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Using CRISPR-Cas9 mediated gene knock out to generate a genomic deletion of FBP1 in cancer cells we observed some clear differences to all previous studies using shRNA or siRNA mediated knock-downs [\u003cspan additionalcitationids=\"CR2 CR3 CR4\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. The results obtained further demonstrate the essential role of FBP1 in metabolic adjustment and confirm the role of FBP1 as an emerging tumour suppressor, and emphasize FBP1\u0026rsquo;s potential to suppress cancer specific glycolysis driven metabolism.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv class=\"Section2\" id=\"Sec3\"\u003e\n \u003ch2\u003eThe ectopic expression of FBP1 slows down MCF-7 proliferation in presence of abundant glucose\u003c/h2\u003e\n \u003cp\u003ePrevious reports indicated an anti-proliferative effect of FBP1 in various cancer types [\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e]. To assess the effect of FBP1 on proliferation, we used the protein-based SRB viability assay to assess the growth rate of stable MCF-7 lineages, in which we established various contexts of FBP1 (Fig S1). Cells with FBP1 over-expression exhibited slower growth than the vector control cells (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003ea). Consistently, knocking out FBP1 increased the growth rate of MCF-7 cells with stable CRISPR-Cas9 deletion compared to the unmodified wild type cells (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003ea). The changes in growth rates were not reflected in the colony formation assay (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003ec). This last finding indicates that FBP1 does not hamper tumorigenesis in this luminal breast cancer subtype, consistent with the positive FBP1 expression in primary and luminal breast cancers [\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e].\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec4\"\u003e\n \u003ch2\u003eFBP1 is essential for glucose autotrophy in MCF-7 cells\u003c/h2\u003e\n \u003cp\u003eOur previous work on yeast established that FBP1 is indispensible for a continued gluconeogenesis flux [\u003cspan class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e16\u003c/span\u003e]. We therefore assessed the proliferation and survival of FBP1-KO cells under glucose depletion. Glucose withdrawal specifically impacted FBP1-KO growth and survival while the wild-type cells continued proliferating. Complete glucose deprivation inhibited the proliferation of FBP1 KO cells starting at 3 days after glucose withdrawal (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eb). Consistently, limiting glucose in medium to 2mM had comparable effects on FBP1-KO. On the contrary, neither diminished glucose nor complete glucose deprivation affected the proliferation of the wild type MCF-7 cells (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eb). This result highlights both the indispensability of FBP1 activity for gluconeogenesis in MCF-7, and also ensures that FBP1 is the only isozyme in these cells capable of catalysing the dephosphorylation of F1,6bP.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec5\"\u003e\n \u003ch2\u003eFBP1 inhibits glucose uptake under a variety of conditions in MCF-7 cells\u003c/h2\u003e\n \u003cp\u003eTo test the impact of FBP1 on glucose uptake in MCF-7 cells, we used 2-NBDG (fluorescence labelled 2-DG). The over-expression of FBP1 inhibited glucose uptake in full DMEM, meanwhile FBP1 KO showed a general trend towards increased glycolysis (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ea). FBP1 over-expression also inhibited glucose uptake upon glucose replenishment and under glutamine deprivation (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eb)., consistent with the reports on the anti-glycolytic effect of FBP1 in various types of cancer [\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e].\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec6\"\u003e\n \u003ch2\u003eFBP1 loss increases glucose utilisation in glycolysis, pentose phosphate pathway and amino acid synthesis\u003c/h2\u003e\n \u003cp\u003eIn line with earlier reports on FBP1 repression as an essential step towards Warburg metabolic rewiring [\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e], we used HPLC-MS metabolite quantification to investigate the metabolic shifts in FBP1 KO MCF-7 cells in contrast with the parental wild-type cells. FBP1 KO cells demonstrated an increased abundance of glycolysis and pentose phosphate pathway intermediates (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ec,d). Increased intracellular and extracellular lactate also indicates an increased glycolytic flux. Unlike the other glycolytic intermediates, phosphoenolpyruvate and pyruvate were both depleted in the FBP1 KO cells. The increase of the intracellular and extracellular lactate on expense of pyruvate is a clear sign of increased aerobic fermentation in the absence of FBP1 (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ec,g). Since pyruvate the most net consumed metabolite by cells (Fig S2), the depletion of pyruvate in medium and the increase in intracellular and medium lactate strongly signifies an overall increase in pyruvate conversion to lactate fuelled by both glycolytic and extracellular pyruvate. Altogether this indicates glucose to lactate metabolic flux, hence a potentiated Warburg effect in the FBP1 KO cells. The depletion of pyruvate and phosphoenolpyruvate in FBP1 KO MCF-7 also coincided with an increase in alanine levels in medium, for which pyruvate is the biosynthetic precursor. Glutamine is the major nitrogen source and amino-acid in DMEM, with 2-D cultured cells showing higher reliance on glutamine compared to spheroids or in-vivo tumours [\u003cspan class=\"CitationRef\"\u003e17\u003c/span\u003e]. The increased level of medium glutamine, observed for the MCF-7 KO cells (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eg), signifies a shift from amino acid to glucose catabolism upon FBP1 loss. Consistently, the overall output of extracellular alanine, which is net released from the cells into the medium (Fig S2), is increased, hence signifying an increased overall amino acid biosynthesis. Moreover, leucine, isoleucine, valine, tyrosine, tryptophan and phenylalanine, all essential amino acids, showed elevated accumulation in FBP1 KO cells hence indicating increased uptake and/or decreased catabolism due to the complete inhibition of gluconeogenesis (Fig S2).\u003c/p\u003e\n \u003ch2\u003eA combination of GAPDH inhibition and of PKM2 activation causes serine depletion in FBP1 KO MCF-7\u003c/h2\u003e\n \u003cp\u003eIntriguingly, and contrary to earlier findings [\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e], FBP1 KO correlated to a significant depletion of intracellular serine and its downstream derivative glycine (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ef). This depletion was not accompanied by shifts of either serine or glycine medium concentrations hence ruling out changes of uptake or secretion (Fig S2), while the activity of PHGDH, the key enzyme for serine biosynthesis [\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e], remained unchanged (Fig S3). Changes in glycolytic enzymatic activity offer a plausible explanation for the unexpected depletion of serine in FBP1 KO cells. We detected inhibited GAPDH activity and increased pyruvate kinase activity in the native protein extracts of the FBP1 KO cells compared to wild type (Fig S3). GAPDH inhibition is a reported mechanism of fuelling the pentose phosphate shunt with G6P [\u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e21\u003c/span\u003e], and it consists with the observed increase of upper glycolytic (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ec), and pentose phosphate pathway intermediates (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ed). FBP1 substrate F1,6bP is a robustly established allosteric activator of PKM2 [\u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e23\u003c/span\u003e], hence the removal of FBP1 spares its substrate allowing the observed activation of PKM2. Together, inhibited GAPDH and activated PKM2 deplete the glycolytic intermediates in between the two enzyme, including 3-PG, the initial substrate of serine biosynthesis (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ec\u0026amp;f).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec7\"\u003e\n \u003ch2\u003eFBP1 impedes glucose sensing and uptake and in MCF-7 cells\u003c/h2\u003e\n \u003cp\u003eTo further assess the impact of FBP1 on glucose sensing, we probed TXNIP expression. TXNIP expression is indirectly induced by the glycolytic intermediates Glucose-6-phosphate G6P and glyceraldehyde-3phosphate GA3P [\u003cspan class=\"CitationRef\"\u003e24\u003c/span\u003e]. Hence TXNIP is completely depleted under glucose deprivation. Under continuous glucose supply, and upon glucose replenishment, FBP1 KO cells exhibited higher levels of TXNIP compared to wild type cells (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003ea,b\u0026amp;c). Consistently, lower levels of TXNIP expression were observed in FBP1 KO cells upon glucose replenishment with varying concentrations (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003ed). To show that increased TXNIP expression is a direct outcome of increased glycolysis intermediates, 2-DG was included as a positive control and elicited sharp increase in TXNIP expression (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003ed).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec8\"\u003e\n \u003ch2\u003eFBP1 correlates with increased ROS accumulation, mitochondrial biomass and decreased mitochondrial inner-membrane potential MIMP\u003c/h2\u003e\n \u003cp\u003eIn light of the observed effects on glucose catabolism and utilisation, we sought to assess the impact of FBP1 on the abundance and function of the mitochondria in addition to the related outcome of ROS accumulation. FACS analysis of DHE stained MCF-7 cells showed increased ROS accumulation in oeFBP1 vs vector control cells; consistently FBP1 KO cells exhibited significantly decreased ROS accumulation (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003ea). Using MitoTracker\u0026reg; Green we similarly established a positive correlation between FBP1 expression and mitochondrial biomass (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003eb), indicative of increased mitochondrial biogenesis in presence of FBP1. However, the increase in mitochondrial biomass with FBP1 expression also coincided with a diminished mitochondrial inner-membrane potential MIMP (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003ec).\u003c/p\u003e\n \u003cp\u003eIn line with the metabolic shift towards increased glucose catabolism and decreased glutamine consumption, we predicted that FBP1 loss would render cells independent of glutamine and more vulnerable to glucose starvation. Indeed, FBP1 absence prevented the additional ROS induction observed in glutamine deprived wild type cells (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003ed), meanwhile the FBP1 KO cells responded to glucose withdrawal by dramatically increasing their mitochondrial biomass to levels significantly higher than the wild type (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003ee). Therefore, suggesting a compensatory response to cope with glucose scarcity by increasing mitochondrial biomass to harness higher levels of energy form a dwindling level of metabolic intermediates.\u003c/p\u003e\n \u003cp\u003eThe increase in mitochondria with lower MIMP can explain the elevated ROS as result of a concomitant increase in the overall mitochondrial inner-membrane area, as a result of increased mitochondrial biomass, and leakiness in the electron transport chain. This also consists with the FBP1 inhibitory effects on mitophagy, since electron transport chain leaking is a hallmark of aging mitochondria.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec9\"\u003e\n \u003ch2\u003eFBP1 deletion diverts ATP production from the ETC\u003c/h2\u003e\n \u003cp\u003eBlocking ATP-synthase with 10\u0026micro;M oligomycin [\u003cspan class=\"CitationRef\"\u003e25\u003c/span\u003e] resulted in significantly smaller increase of mitochondrial polarisation in FBP1 KO MCF-7 cells compared to the wild type (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003ef). The increased polarisation reflects directly the amount of protons that would path through ATP-synthase and contribute to ATP production; hence we conclude that FBP1-deficinecy limited the reliance of MCF-7 on the electron transport chain ETC for ATP production.\u003c/p\u003e\n \u003cp\u003eThis consists with the increased glucose consumption, utilisation and aerobic fermentation observed in the FBP1-KO cells.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec10\"\u003e\n \u003ch2\u003eFBP1-loss provides a survival advantage under extreme hypoxia\u003c/h2\u003e\n \u003cp\u003eThe increased glucose utilisation and aerobic fermentation we observed for FBP1 KO cells consist with the conventional Warburg effect, and should coincide with decreased reliance on respiration. Hence we investigated the survival of MCF-7 FBP1-KO cells under hypoxia compared to wild type cells. Both SRB growth/survival assay (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003ea\u0026amp;b) and FACS analysis of PI-stained cells (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003ec) showed a statistically valid advantage for FBP1-deficeint MCF-7 cells over the wild type cells following incubations at 1% O2 saturation, SRB assays were for a time frame of 24h to 96h under hypoxia, while PI staining was performed following 48h under 1% O2 saturation.\u003c/p\u003e\n \u003ch2\u003eMDA-MB-231 cells acquire the capacity to degrade ectopic FBP1 in a proteasome dependent mechanism upon long-term selection\u003c/h2\u003e\n \u003cp\u003eTo better understand the metabolic and proliferative advantages of FBP1 silencing, we aimed to determine the effects of ectopic FBP1 in the triple-negative MDA-MB-231 cells, with depleted FBP1 expression. To our surprise the stable expression of FBP1, following a minimum of 6 weeks of geneticin selection, yielded diminished levels of FBP1 expression compared to the FBP1-positive MCF-7 (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003ea). This was despite transient expression in MDA-MB-231 successfully yielding substantial levels of expression (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eb). Quantitative PCR also showed an increase in \u003cem\u003eFBP1\u003c/em\u003e mRNA levels in MDA-MB-231 stable oeFBP1 cells, greater than that observed in MCF-7 oeFBP1 (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003ec).\u003c/p\u003e\n \u003cp\u003eAltogether this indicated the potential of post-translational protein degradation as an underlying mechanism of the attenuated FBP1 expression in MDA-MB-231 cells.\u003c/p\u003e\n \u003cp\u003eTo test this possibility we resorted to pharmacological proteasome inhibition [\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e]. Indeed, bortezomib treatment rescued FBP1 protein expression in MDA-MB-231 cells with stable FBP1 ectopic expression while showing no effect on FBP1 in the control MDA-MB-231 cells harbouring the empty vector (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003ed). To verify the rescuing effect of proteasome inhibition on ectopic FBP1 expression in MDA-MB-231 cells we also used MG132, another more distinctive proteasome inhibitor [\u003cspan class=\"CitationRef\"\u003e27\u003c/span\u003e], with comparable outcome to that observed with bortezomib (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003ee). We are the first to observe such degradation of FBP1 in breast cancer cells, a similar effect has been found to contribute to FBP1 ablation in hepatocellular carcinoma [\u003cspan class=\"CitationRef\"\u003e28\u003c/span\u003e].\u003c/p\u003e\n \u003cp\u003eUpon bortezomib treatment, the rescued ectopic FBP1 expression also inhibited glucose uptake compared to the vector control cells (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003ef), similar to its identified role in MCF-7. Moreover, the transient transfection with FBP1, correlated to higher levels of expression, decreased acidification rates in MDA-MB-231 cells indicting slowed down glycolysis (Fig S4).\u003c/p\u003e\n \u003ch2\u003eGlutamine as an exclusive carbon source stabilizes ectopic FBP1 expression in MDA-MB-231 cells and confreres a growth disadvantage to oeFBP1 cells\u003c/h2\u003e\n \u003cp\u003eWe next sought to assess the interplay between the ectopic FBP1 expression in MDA-MB-231 and nutrient availability in the culture medium. The post-translational proteasome-dependent degradation of FBP1 has long been described as a part of the more encompassing phenomenon of carbon catabolite inactivation in unicellular eukaryotes [\u003cspan class=\"CitationRef\"\u003e29\u003c/span\u003e]. Glucose is the most prominent metabolite to trigger the signalling cascade, which leads to FBP1 phosphorylation, ubiquitination, and degradation both in the proteasome and the vacuole [\u003cspan class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e31\u003c/span\u003e]. Therefore, we asked whether this mechanism is conserved in human cells. If so, the constitution and balance of carbon sources in cell culture medium should influence the observed levels of ectopic FBP1 by altering its degradation rate.\u003c/p\u003e\n \u003cp\u003eFirst, we observed via proliferation SRB assays that the marginal amounts of stably expressed FBP1 in MDA-MB-231 were advantageous under full DMEM containing both glucose and glutamine (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003ea), as well as under high glucose concentration (75mM) with NH4Cl as the exclusive nitrogen source (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eb), the successful utilisation of ammonia by breast cancer cells has been clearly demonstrated [\u003cspan class=\"CitationRef\"\u003e32\u003c/span\u003e]. To our surprise however, the growth of oeFBP1 MDA-MB-231 cells was severely challenged in medium with high levels of glutamine (8mM) as the exclusive carbon and nitrogen source (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003ec). This is very intriguing in light of glutamine being a major gluconeogenic substrate. Consistently, immunoblotting showed remarkable increase in ectopic FBP1 levels under glucose depletion coupled with high glutamine concentrations (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003ed), thus indicating an attenuation of FBP1 degradation under this condition.\u003c/p\u003e\n \u003cp\u003eThis is to our knowledge the first reported evidence on the effect of the availability of various carbon sources on FBP1 proteasomal degradation in human cancerous cells and mammalian cells in general. Hence indicating a likely carbon catabolite inactivation phenomenon akin to that characterised in yeast.\u003c/p\u003e\n \u003cp\u003eDespite its advantageous effect on proliferation, the presence of marginal ectopic FBP1 in oeFBP1 cells tangibly inhibited colony formation capacity (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003ee), consistent with the known aspects of FBP1 repression in basal-like and metastasising breast cancer.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec11\"\u003e\n \u003ch2\u003eStable and transient FBP1 expression lead to contrasting oxidative and mitochondrial outcomes in MDA-MB-231 cells\u003c/h2\u003e\n \u003cp\u003eCompared to its effect in MCF-7, the stable expression of FBP1 in MDA-MB-231 unexpectedly correlated to a steep decrease in ROS levels as measured using DHE (Fig S5a). However, transient expression yielding comparable levels of FBP1 to those of MCF-7 had no significant effect on ROS accumulation (Fig S5d), despite a slight trend towards increased ROS. The investigated mitochondrial markers, on the other hand, reacted similarly to the expression of FBP1 in MDA-MB-231 in a manner comparable to the observations in MCF-7. MDA-MB-231 cells with stable FBP1 expression exhibited lower mitochondrial inner-membrane polarisation and higher total mitochondrial biomass (Fig S5b\u0026amp;c).\u003c/p\u003e\n \u003cp\u003eTransient FBP1 over-expression however yielded elevated mitochondrial polarisation (Fig S5e), hence possibly indicating an increase in respiratory activity upon FBP1 ectopic expression later followed by increased mitochondrial biogenesis.\u003c/p\u003e\n \u003ch2\u003eComparing transcriptional profiles signified a wide-scale cell-cycle inhibitory effect of long term FBP1 expression in MDA-MB-231 cells\u003c/h2\u003e\n \u003cp\u003eHaving observed that MDA-MB-231 cells adapt to FBP1 long-term expression by degrading FBP1 in the proteasome, we were intrigued to assess the shifts in transcription that can indicate the types of alterations occurring as a result of ectopically expressing FBP1 in MDA-MB-231 cells. Therefore, we used the Illumina RNA microarray system for a full transcriptome scale quantification of gene-expression of stable oeFBP1 vs vector control MDA-MB-231 cells.\u003c/p\u003e\n \u003cp\u003eFollowing the basic quantification of fold changes in FBP1 over-expression \u003cem\u003evs\u003c/em\u003e vector control cells, we performed a wide analysis of the impact of FBP1 over-expression on gene-expression patterns in MDA-MB-231 including a larger pool of up-regulated (\u0026ge;1.6 folds) and down-regulated (\u0026le;0.65 folds) genes (Figure S6). Using the STRING functional protein association network, two separate schemes of interaction networks between the proteins encoded by the up-regulated and down-regulated genes were made. Comparing the two interaction networks, the most noticeable difference is the clear arrangement of the down-regulated genes into an interaction-rich network (Fig S6a). At the centre of this network are proteins associated with the cell cycle progression; the vast majority are proteins essential for mitosis and cytokinesis (M-Phase) these include the centrosome proteins CENP- A,E,M,N, aurora kinase A AURK-A and its activator TPX, the kinesin family members KIFs 2C, 4A, 20A, 20B, 23 and the centrosomal protein CEP55. Besides M-phase proteins, several other genes encoding for essential cell-cycle proteins are also seen within the aforementioned interaction network. These include, the Cyclin A2 essential for the cell cycle progression G1/S and G2/M transitions through activating CDK1 (also among the down-regulated genes) and CDK2. Other down-regulated genes include the histone cluster 2 (H2AC and H2AA3) in addition to thymidilate synthetase essential for thymidine de-novo biosynthesis and the exonuclease 1 EXO1 essential for DNA-mismatch repair. In contrast with the heavy interactions observed between the down-regulated genes, the interactions among the up-regulated genes are scarce. Therefore no wider conclusions regarding the up-regulation of entire signalling pathways or cellular functions could be drawn.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec12\"\u003e\n \u003ch2\u003eImmunoblotting confirmed the FBP1-associated inhibition of CENP-E\u003c/h2\u003e\n \u003cp\u003eIn order to test the observed cell-cycle inhibition on a protein level, immunoblots of short-term transfected MDA-MB-231 cells were performed. HT-29 cells were also included to test the validity of our findings in other FBP1-deficeint cell lines of other tumor origins. Consistent with the transcriptional findings, the ectopic expression of FBP1 correlated to diminished CENP-E levels in both tested cell lines (Fig. \u003cspan class=\"InternalRef\"\u003e8\u003c/span\u003e). This finding validates the functional relevance of the cell cycle inhibition seen in the transcriptional profiling.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis work aimed at investigating FBP1 as an emerging tumour suppressor in the context of breast cancer using cell lines representing the luminal and basal-like major subtypes. We studied the effects of FBP1-loss by establishing CRISPR-Cas9 knock-out of FBP1 in MCF-7 cells and characterising the resulting knock-out cell population against the otherwise genetically-identical parental MCF-7 population. Hence we are the first to share evidence from a genomic knock-out of FBP1 in cancer cells to support the tumour suppressor role ascribed to FBP1, its anti-glycolytic metabolic activity, and FBP1 repression as an important step towards aerobic glycolysis and fermentation typical to the Warburg effect [\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e]. Nonetheless, several particularities were identified for each cell type in regards to their response to ectopic FBP1 expression.\u003c/p\u003e\n\u003cp\u003eWhile the additional FBP1 over-expression in MCF-7 presented a burden on growth and glucose utilisation, the endogenously FBP1-repressed MDA-MB-231 adapted to the long-term expression of FBP1 by post-translational degradation. This left a marginal amount of FBP1 upon selection of MDA-MB-231 with stable FBP1 expression. This minute amount of FBP1 expression had favourable effects for growth under glucose, and inhibited ROS accumulation. To the contrary, interventions to restore high levels of the ectopically expressed FBP1 by proteasomal inhibition or growing cells with glutamine as the restrictive carbon source, unmasked the anti-proliferative and glucose uptake inhibition associated to high levels of FBP1 as in MCF-7 cells. Similarly, the transient expression in MDA-MB-231 yielded higher levels of expression and associated to inhibition of cellular acidification, did not inhibit ROS accumulation, and exhibited comparable effects on mitochondrial variables to those observed with oeFBP1 in MCF-7. In line with earlier findings, FBP1-associated increase in mitochondrial biomass also correlated with diminished survival under hypoxia indicating increased reliance on respiration in contexts of FBP1 expression. A similar pro respiratory effect and enhanced mitochondrial activity is common to other interventions that disrupt glycolysis, as we reported very recently in regards to the effect of concentrated ascorbate on breast cancer cells [\u003cspan class=\"CitationRef\"\u003e33\u003c/span\u003e]. Furthermore, respiratory effects of FBP1 is probably an outcome of interplay between its negative impact on glycolytic flux and its non-catalytic role as a negative co-regulator of HIF1-alpha, which has been thoroughly described in renal cancer [\u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e]. The presence of an identical mechanism in breast cancer is highly plausible, especially that a non-catalytic role of FBP1 in preventing snail mediated EMT has already been described in breast cancer cells [\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e], which suggests the possibility of a non-catalytic protein-protein interaction allowing FBP1 to function as a co-regulator of gene expression. Consistent with earlier works on FBP1 in breast and renal cancers [\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e34\u003c/span\u003e], we showed evidence of increased mitochondrial biomass and reliance on respiration for energy generation and survival. The links between FBP1 and mitochondrial homeostasis and function offer a potential mechanism for interventions to target tumour metabolism and abrogate the transition towards aerobic fermentation by fostering cellular respiration using FBP1 metabolite activation [\u003cspan class=\"CitationRef\"\u003e35\u003c/span\u003e] and epigenetic interventions to prevent FBP1 repression in cancer cells and/or precancerous lesions [\u003cspan class=\"CitationRef\"\u003e36\u003c/span\u003e]. Moreover, the FBP1-associated increase in mitochondrial mass and the reported prolonged mitochondrial retention due to inhibited mitophagy both suggest potential relevance of FBP1 and gluconeogenesis to aging and longevity. It is widely accepted that cumulative damage to the mtDNA and respiratory chain majorly contribute to aging [\u003cspan class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e38\u003c/span\u003e]. Hence the effects of FBP1 and gluconeogenesis on the mitochondrial homeostasis of aging cells could be relevant to longevity [\u003cspan class=\"CitationRef\"\u003e39\u003c/span\u003e]. This is relevant in light of the potential nutritional regulation of FBP1 expression, for which our preliminary results already show a promise for modulating FBP1 levels in cancer cell lines by altering nutrients availability. It did not escape our attention that the stabilisation of ectopic FBP1 under glucose restriction and glutamine abundance could constitute a hitherto unobserved form of carbon catabolite repression of FBP1 in mammalian cells, similar to the well-characterised phenomenon in yeast [\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e29\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eProposed mechanism of dynamic FBP1 regulation light of the glucose-mediated post-translational inactivation of FBP1. Based on our observations we speculate that epigenetic silencing of FBP1 in cancer cells is incomplete and not sufficient for the metabolic adjustment driving cancer metabolism. Thus, silencing of FBP1 is complemented by post-translational repression. Vice versa, glucose withdrawal allows for the restoration of FBP1 expression in a self-sustaining cycle: diminished glucose levels alleviate the proteasomal degradation and the increased FBP1 level further inhibits glucose uptake and glycolysis and therefore keeps the glucose-mediated FBP1 post-translational inactivation at bay.\u003c/p\u003e\n\u003cp\u003eSince we reached these findings in cell culture by applying extreme and physiologically irrelevant conditions of glucose deprivation it remains to be seen how this mechanism applies in-vivo both in cancer cells, precancerous lesions, and under normal physiology in normal cells.\u003c/p\u003e\n\u003cp\u003eWith that said and considering the newly described relevance of FBP1 to transcriptional control, the above described mechanisms of FBP1 restoration could open a door for the metabolic rewiring of cancer cells diverting them away from the Warburg model and limiting aggressiveness. Uncovering the in-vivo physiology of FBP1 post-translational control would be very relevant to both cancer and metabolic disease since it would mean that dietary and nutritional intervention can contribute to the long term sustenance or ablation of FBP1 expression. Furthermore, the dynamic effect of nutrient availability on FBP1 expression in cancer cells makes space for speculation regarding a plausible mechanism of the robust anti-cancer effect attributed to metformin in wide population studies showing diminished cancer risk in type-II diabetics on metformin [\u003cspan class=\"CitationRef\"\u003e40\u003c/span\u003e]. In this mechanism the glucose lowering effect of metformin, especially via blocking the hepatic gluconeogenesis [\u003cspan class=\"CitationRef\"\u003e41\u003c/span\u003e], would have a stabilising effect on FBP1 expression in the periphery and preserve its quasi tumour suppressor role. We are therefore focused on further identifying the molecular mechanism, magnitude, and versatility of this effect.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eIn this study we provided the first genomic-based evidence on the relevance of FBP1 to the emergence of Warburg effect. We also demonstrated for the first time the capability of particular breast cancer cells to degrade FBP1 as a response to its enforced ectopic expression. Moreover, we also analysed the effect of nutrient availability in the culture medium on FBP1 mediated effects on cellular proliferation and survival.\u003c/p\u003e\n\u003cp\u003eOur current and future work will focus on identifying the exact mechanism behind FBP1 post-translational regulation in cancer cells in the hope of identifying physiologically relevant mechanisms contributing to FBP1 ablation in cancer initiation and progression, in addition to metabolic diseases.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell culture:\u0026nbsp;\u003c/strong\u003ethe cell-lines MCF-7, MDA-MB-231 (ATCC) were incubated at 37\u0026deg; and 5% CO2. All passaging, cultivation, seeding and treatments were performed in Dublecco\u0026rsquo;s modified eagle medium DMEM (Gibco, Germany) for details refer to \u003cstrong\u003eSupp. Methods I\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003eMCF-7 and MDA-MB-231 cells (ATCC) were obtained in 2012, preserved in liquid nitrogen and utilized for experiments in passage between 15 and 30. Cells were also tested for mycoplasma. Further details in \u003cstrong\u003eSupp. Methods I\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003eCells were treated with various media conditions as indicated, fresh DMEM was prepared from scratch with glucose, glutamine, and NH4Cl added freshly to reach the indicated concentrations. For proteasome inhibition, bortezomib (Selleckchem\u0026reg;) and MG132 (Sigma-Aldrich\u0026reg;) were used.\u003c/p\u003e\n\u003cp\u003e\u003c/p\u003e\n\u003cdiv class=\"Section2\" id=\"Sec16\"\u003e\n \u003ch2\u003eMolecular cloning and construction of plasmids\u003c/h2\u003e\n \u003cp\u003eTo establish ectopic expression of FBP1 in the tested cell lines, new plasmids were constructed with FBP1 variants expressed under a constitutive mammalian promoter. For this purpose I started with the commercially available pcDNA3.1(-) vector.\u003c/p\u003e\n \u003cp\u003e(For the detailed method please refer to the \u003cstrong\u003eSupp. Methods II\u003c/strong\u003e)\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec17\"\u003e\n \u003ch2\u003eTransfection of cell lines and establishing stable over-expressions and deletions\u003c/h2\u003e\n \u003cp\u003eLipid-based transfection was used, Lipofectamin\u003csup\u003eTM\u003c/sup\u003e3000 (Thermo Fisher\u0026reg;, Waltham MA), for introducing the FBP1 over-expression or CRISPR-Cas9 deletion vectors into the cell lines. The transfections were performed using the protocols provided with the transfection reagents.\u003c/p\u003e\n \u003cp\u003e(The detailed methods of trnasfection and establishing the stable cell lineages in the \u003cstrong\u003eSupp. Methods III\u003c/strong\u003e)\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec18\"\u003e\n \u003ch2\u003eProtein extraction for immunoblotting\u003c/h2\u003e\n \u003cp\u003eTo extract total proteins from cells, 3*10\u003csup\u003e5\u003c/sup\u003e to 5*10\u003csup\u003e5\u003c/sup\u003e cells were seeded, following 24 to 48 hours of incubation cells were subjected to the desired treatment or medium conditions and then lysed in 6 M urea buffer containing the following protease inhibitors: (NaF, PMSF, Pepstatin, Aprotenine and NaVO\u003csub\u003e4\u003c/sub\u003e). To lyse the cells, medium was aspirated, and 120 to 180 \u0026micro;l ice-cold 6 M Urea buffer were pipetted directly onto the cells. Subsequently, the cell culture plates were promptly placed on ice and then vortexed to ensure full homogenization in the Urea buffer. Afterwards, lysates were collected in Eppendorf tubes and then spun down at 13000 g for 15 minutes to get rid of the DNA. Lysates were subsequently stored at -20\u0026deg;C.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec19\"\u003e\n \u003ch2\u003eDetermining total protein concentrations\u003c/h2\u003e\n \u003cp\u003eTotal protein concentrations in the lysates were determined using Bradford reaction. 10 \u0026micro;l of each lysates were mixed with 990 \u0026micro;l of Bradford reagent (Sigma-Aldrich) in Eppendorf tubes. Samples were then mixed and incubated for 5 minutes in the dark. Subsequently 3x300 \u0026micro;l of each sample were transferred into 96 well-plates and measured using the Tecan Ultra (Tecan, Germany) reader at 595 nm.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec20\"\u003e\n \u003ch2\u003eSDS-PAGE and immunoblotting\u003c/h2\u003e\n \u003cp\u003eProteins in denatured lysates were resolved on 10% polyacrylamide gel (SDS-PAGE) as described in (Laemmli, 1970)[\u003cspan class=\"CitationRef\"\u003e42\u003c/span\u003e]. Afterwards, resolved proteins were blotted (transferred) from the resolving SDS-PAGE gel onto a PVDF membrane. Semi-dry protein transfer was used with anode and cathode buffer prepared as detailed in the above material section.\u003c/p\u003e\n \u003cp\u003eSubsequently, membranes were stained with ponceau S (5% ponceau S) and then washed in TBS-tween 1% \u003cem\u003e(v/v)\u003c/em\u003e buffer and blocked in a 5% BSA solution in TBS-tween buffer for 1 hour, and then incubated with 1:1000 solution of one of the used primary antibodies. After the primary anti-body incubation, membranes were washed 3 times for 5 minutes each in TBS-tween 1 buffer and subsequently incubated in 1:5000 HRP-fused anti rabbit or anti mouse secondary (IgG) anti-body solutions for 1 hour. Finally, membranes were washed 3 x 5 minutes and developed in Western Lightning Plus-ECL (Perkin-Elmer, Germany). Signals were detected using the Fujifilm LAS-3000 imaging system and the AIDA software for image acquisition.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec21\"\u003e\n \u003ch2\u003eQuantification of western-blot signals\u003c/h2\u003e\n \u003cp\u003ethe intensities of the western-blot bands of target proteins were quantified using the Image-J histogram quantification tool. The intensity of the target protein signals was adjusted relative to the corresponding loading-control (beta-actin) bands.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec22\"\u003e\n \u003ch2\u003eSRB Survival and growth assays\u003c/h2\u003e\n \u003cp\u003eThe total-protein based SRB colourimetric assay was used to assess cell survival and growth of cells with various FBP1 contexts under the indicated media conditions/treatments.\u003c/p\u003e\n \u003cp\u003eThe utilised SRB-assay protocol was derived from Vichai and Kirtikara 2006 [\u003cspan class=\"CitationRef\"\u003e43\u003c/span\u003e].\u003c/p\u003e\n \u003cp\u003eFor the detailed SRB method refer to the \u003cstrong\u003eSupp. Methods IV\u003c/strong\u003e)\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec23\"\u003e\n \u003ch2\u003eFACS analysis\u003c/h2\u003e\n \u003cp\u003eFluorescence activated cell sorting FACS analysis was used to measure a variety of metabolic and viability markers in the cells. Cells were seeded in 12 well plates at a density of 50,000 cells/well in 1 ml full DMEM/well and incubated over-night. On the following day medium was aspirated, and cells were treated as indicated for each experiment). Following treatment, cells were incubated with the fluorescent probes) then analysed using FACS Guava (Merck-Millipore, UK).\u003c/p\u003e\n \u003cp\u003eThe following probes were used; 2-NBDG for glucose uptake[\u003cspan class=\"CitationRef\"\u003e44\u003c/span\u003e], DHE for intracellular ROS accomulation [\u003cspan class=\"CitationRef\"\u003e45\u003c/span\u003e], MitTracker Green for mitochondrial mass, and JC-1 for mitochondrial inner-membrane potential.\u003c/p\u003e\n \u003cp\u003e(Detailed methods and mechanisms for each fluorescent probe are listed in the \u003cstrong\u003eSupp. Methods V.)\u003c/strong\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec24\"\u003e\n \u003ch2\u003eLiquid chromatography-mass spectrometry based metabolite quantification:\u003c/h2\u003e\n \u003cp\u003eIntracellular metabolites were extracted and quantified using an LC-MS based method as previously described in [\u003cspan class=\"CitationRef\"\u003e46\u003c/span\u003e]. Details in \u003cstrong\u003eSupp. Methods VI\u003c/strong\u003e.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec25\"\u003e\n \u003ch2\u003eExtraction of RNA from cultured cells\u003c/h2\u003e\n \u003cp\u003eCells were seeded in full DMEM in six-well plates at a density of 2x10\u003csup\u003e5\u003c/sup\u003e cells/well. After 1 day cells were treated, or transfected as indicated, and after the indicated duration of treatment mRNA was extracted using the following triazole/chloroform method.\u003c/p\u003e\n \u003cp\u003e(For the detailed methods of the mRNA extraction refer to the \u003cstrong\u003eSupp. Methods VII\u003c/strong\u003e.)\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec26\"\u003e\n \u003ch2\u003eComplementary DNA (cDNA) synthesis\u003c/h2\u003e\n \u003cp\u003eThe synthesis of cDNA from the isolated RNA was carried out using the ProtoScript\u0026reg; First Strand Synthesis kit from NEB\u0026reg;.\u003c/p\u003e\n \u003cp\u003eThe cDNA was synthesised using the protocol provided with the kit. To ensure that the mRNA is exclusively reverse-trscribed without other RNA types in the mixture, the reverse transcription was performed using poly-t primers that anneal specifically to the poly-A tails of the mRNA transcripts.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec27\"\u003e\n \u003ch2\u003eReal-time quantitative PCR rt-qPCR\u003c/h2\u003e\n \u003cp\u003eFor the quantitative PCR the LightCycler\u0026reg; Sybr Green (Roche\u0026reg;) reaction mix was utilized. The reactions were prepared according to the following protocol:\u003c/p\u003e\n \u003cp\u003eThe following master-mix was prepared for each primer pair (target gene) to be tested. Quantities are giver for 1 reaction:\u003c/p\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eCybr Green\u0026reg;: 2.5 \u0026micro;l\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003ePrimer Mix: 1 \u0026micro;l\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eNuclease free water: 0.5 ml\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n \u003cp\u003ePipetted onto 1 \u0026micro;l of cDNA (concnetration\u0026asymp;30 ng/\u0026micro;l)\u003c/p\u003e\n \u003cp\u003eThe tested cDNAs were pipetted in Microplate 96 LP (Analytik Jena AG) compatible to the qTOWER real-time PCR thermal cycler (Analytik Jena AG).\u003c/p\u003e\n \u003cp\u003e4 \u0026micro;l of the master-mix were pipetted in triplets on each type of the tested cDNAs. Subsequently, the plates were fed into the qTower real-time PCR thermal cycler, where the reactions occurred and the results were obtained.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec28\"\u003e\n \u003ch2\u003eQuantitative interpretation of the qPCR data\u003c/h2\u003e\n \u003cp\u003eThe mean values of the yielded CT of each triplet or reactions were calculated, including the mean-values of each tested cDNA with the reference genes. Then using these mean values of the CT of each target and reference genes, relative expression of the target genes was compared for the different cDNAs (treated vs non-treated or transfected vs empty vector) using the ∆∆CT equation to yield the relative expression values:\u003c/p\u003e\n \u003cp\u003e∆Ct=Ct\u003csub\u003e(target gene)\u003c/sub\u003e-Ct\u003csub\u003e(reference gene)\u003c/sub\u003e for a given sample.\u003c/p\u003e\n \u003cp\u003e∆∆Ct=∆Ct\u003csub\u003e(treated sample)\u003c/sub\u003e-∆Ct(control sample)\u003c/p\u003e\n \u003cp\u003eRelative expression (Fold change)=-2\u003csup\u003e∆∆Ct\u003c/sup\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec29\"\u003e\n \u003ch2\u003eTranscriptional profiling of MDA-MB-231 cells\u003c/h2\u003e\n \u003cp\u003eRNA was extracted from 500.000 cells. RNA concentrations were adjusted to 100ng/\u0026micro;l and samples were sent to collaborators in the Functional Genome Analysis Division in DKFZ (Lab of Professor J\u0026ouml;rg Hoheisel), were they were analysed using the Illumina RNA microarray system. The utilised method was described in previously published research from the group [\u003cspan class=\"CitationRef\"\u003e47\u003c/span\u003e]and is summarised below:\u003c/p\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003eRNA-integrity of the samples was verified using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto).\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eThe analysis of the total RNA in the samples was performed using Sentrix Human-6v3 Whole Genome Expression BeadChips (Sentrix Human WG-6; Illumina).\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003eFollowing hybridisation to the chips according to the manufacturer\u0026rsquo;s instructions, the arrays were scanned with a BeadArray Reader (Illumina).\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec30\"\u003e\n \u003ch2\u003eColony forming assay\u003c/h2\u003e\n \u003cp\u003eCells with different FBP1 expression were seeded in 6 well plates at the extra-low density of 300 cells/well in 2 ml full DMEM, refreshed every 7 days. After 2 weeks (MDA-MB-231) or 3 weeks (MCF-7) of incubation colonies were fixed and stained using a PBS solution containing 0.021% \u003cem\u003e(v/v)\u003c/em\u003e formaldehyde and 0.5% \u003cem\u003e(w/v)\u003c/em\u003e crystal violet.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no conflict of interests. \u003cstrong\u003e \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConcept and experimental design A.G. and S.W.; Experimentation; A.G. and B.T.; Methodology A.G. and S.W.; Funding and Supervision S.W.; Data analysis and interpretation A.G. and S.W.; Data presentation and figure design A.G. and S.W.; drafting the manuscript A.G. and S.W. All authors read and approved the manuscript before submission. \u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA.G. received a DAAD fellowship to pursue his PhD in the W\u0026ouml;lfl Lab, parts of this study were also supported by BMBF funding with the following grants FKZ 01EK1612C and FKZ 031A303E. We would also like to acknowledge the financial support from the DFG and Heidelberg University within the Open Access Publishing. \u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe thank Esther Zaal and Celia Berkers (Utrecht University) for their support with the metabolite quantification using HPLC-MS in addition to Andrea Bauer and J\u0026ouml;rg Hoheisel (DKFZ) for their support with preliminary transcriptional profiling. \u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical approval and consent to participate and consent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe conducted our study in standard breast cancer cell lines with no patient material or animals involved. Hence no ethical approval or consents were required. \u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and material \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll data and material connected to this work are available and can be provided upon request. \u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eChen M, Zhang J, Li N, Qian Z, Zhu M, Li Q, Zheng J, Wang X, Shi G: \u003cb\u003ePromoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer\u003c/b\u003e. \u003cem\u003ePLoS One\u003c/em\u003e 2011, \u003cb\u003e6\u003c/b\u003e(10):e25564.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, Lin Y, Yao J, Shi J, Kang T \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eLoss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer\u003c/b\u003e. \u003cem\u003eCancer Cell\u003c/em\u003e 2013, \u003cb\u003e23\u003c/b\u003e(3):316\u0026ndash;331.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eFructose-1,6-bisphosphatase opposes renal carcinoma progression\u003c/b\u003e. \u003cem\u003eNature\u003c/em\u003e 2014, \u003cb\u003e513\u003c/b\u003e(7517):251\u0026ndash;255.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang J, Wang J, Xing H, Li Q, Zhao Q, Li J: \u003cb\u003eDown-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells\u003c/b\u003e. \u003cem\u003eMol Cell Biochem\u003c/em\u003e 2016, \u003cb\u003e411\u003c/b\u003e(1-2):331\u0026ndash;340.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhu Y, Shi M, Chen H, Gu J, Zhang J, Shen B, Deng X, Xie J, Zhan X, Peng C: \u003cb\u003eNPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells\u003c/b\u003e. \u003cem\u003eOncotarget\u003c/em\u003e 2015, \u003cb\u003e6\u003c/b\u003e(25):21443\u0026ndash;21451.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSheng H, Ying L, Zheng L, Zhang D, Zhu C, Wu J, Feng J, Su D: \u003cb\u003eDown Expression of FBP1 Is a Negative Prognostic Factor for Non-Small-Cell Lung Cancer\u003c/b\u003e. \u003cem\u003eCancer Invest\u003c/em\u003e 2015, \u003cb\u003e33\u003c/b\u003e(5):197\u0026ndash;204.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi J, Wang Y, Li QG, Xue JJ, Wang Z, Yuan X, Tong JD, Xu LC: \u003cb\u003eDownregulation of FBP1 Promotes Tumor Metastasis and Indicates Poor Prognosis in Gastric Cancer via Regulating Epithelial-Mesenchymal Transition\u003c/b\u003e. \u003cem\u003ePLoS One\u003c/em\u003e 2016, \u003cb\u003e11\u003c/b\u003e(12):e0167857.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHirata H, Sugimachi K, Komatsu H, Ueda M, Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eDecreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma\u003c/b\u003e. \u003cem\u003eCancer Res\u003c/em\u003e 2016, \u003cb\u003e76\u003c/b\u003e(11):3265\u0026ndash;3276.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi H, Li M, Pang Y, Liu F, Sheng D, Cheng X: \u003cb\u003eFructose1,6bisphosphatase1 decrease may promote carcinogenesis and chemoresistance in cervical cancer\u003c/b\u003e. \u003cem\u003eMol Med Rep\u003c/em\u003e 2017, \u003cb\u003e16\u003c/b\u003e(6):8563\u0026ndash;8571.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCheng P, Wang Z, Hu G, Huang Q, Han M, Huang J: \u003cb\u003eA prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy\u003c/b\u003e. \u003cem\u003eOncotarget\u003c/em\u003e 2017, \u003cb\u003e8\u003c/b\u003e(61):103327\u0026ndash;103339.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang H, La Russa M, Qi LS: \u003cb\u003eCRISPR/Cas9 in Genome Editing and Beyond\u003c/b\u003e. \u003cem\u003eAnnu Rev Biochem\u003c/em\u003e 2016, \u003cb\u003e85\u003c/b\u003e:227\u0026ndash;264.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDoudna JA, Charpentier E: \u003cb\u003eGenome editing. The new frontier of genome engineering with CRISPR-Cas9\u003c/b\u003e. \u003cem\u003eScience\u003c/em\u003e 2014, \u003cb\u003e346\u003c/b\u003e(6213):1258096.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoore JD: \u003cb\u003eThe impact of CRISPR-Cas9 on target identification and validation\u003c/b\u003e. \u003cem\u003eDrug Discov Today\u003c/em\u003e 2015, \u003cb\u003e20\u003c/b\u003e(4):450\u0026ndash;457.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLu Q, Livi GP, Modha S, Yusa K, Macarron R, Dow DJ: \u003cb\u003eApplications of CRISPR genome editing technology in drug target identification and validation\u003c/b\u003e. \u003cem\u003eExpert Opin Drug Discov\u003c/em\u003e 2017, \u003cb\u003e12\u003c/b\u003e(6):541\u0026ndash;552.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGhanem A, Kitanovic A, Holzwarth J, Wolfl S: \u003cb\u003eMutational analysis of fructose-1,6-bis-phosphatase FBP1 indicates partially independent functions in gluconeogenesis and sensitivity to genotoxic stress\u003c/b\u003e. \u003cem\u003eMicrob Cell\u003c/em\u003e 2017, \u003cb\u003e4\u003c/b\u003e(2):52\u0026ndash;63.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKitanovic A, Wolfl S: \u003cb\u003eFructose-1,6-bisphosphatase mediates cellular responses to DNA damage and aging in Saccharomyces cerevisiae\u003c/b\u003e. \u003cem\u003eMutat Res\u003c/em\u003e 2006, \u003cb\u003e594\u003c/b\u003e(1-2):135\u0026ndash;147.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuir A, Danai LV, Vander Heiden MG: \u003cb\u003eMicroenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies\u003c/b\u003e. \u003cem\u003eDis Model Mech\u003c/em\u003e 2018, \u003cb\u003e11\u003c/b\u003e(8).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHammerle M, Bauer J, Rose M, Szallies A, Thumm M, Dusterhus S, Mecke D, Entian KD, Wolf DH: \u003cb\u003eProteins of newly isolated mutants and the amino-terminal proline are essential for ubiquitin-proteasome-catalyzed catabolite degradation of fructose-1,6-bisphosphatase of Saccharomyces cerevisiae\u003c/b\u003e. \u003cem\u003eJ Biol Chem\u003c/em\u003e 1998, \u003cb\u003e273\u003c/b\u003e(39):25000\u0026ndash;25005.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKuehne A, Emmert H, Soehle J, Winnefeld M, Fischer F, Wenck H, Gallinat S, Terstegen L, Lucius R, Hildebrand J \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eAcute Activation of Oxidative Pentose Phosphate Pathway as First-Line Response to Oxidative Stress in Human Skin Cells\u003c/b\u003e. \u003cem\u003eMol Cell\u003c/em\u003e 2015, \u003cb\u003e59\u003c/b\u003e(3):359\u0026ndash;371.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRalser M, Wamelink MM, Kowald A, Gerisch B, Heeren G, Struys EA, Klipp E, Jakobs C, Breitenbach M, Lehrach H \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eDynamic rerouting of the carbohydrate flux is key to counteracting oxidative stress\u003c/b\u003e. \u003cem\u003eJ Biol\u003c/em\u003e 2007, \u003cb\u003e6\u003c/b\u003e(4):10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDick TP, Ralser M: \u003cb\u003eMetabolic Remodeling in Times of Stress\u003c/b\u003e: \u003cb\u003eWho Shoots Faster than His Shadow?\u003c/b\u003e \u003cem\u003eMol Cell\u003c/em\u003e 2015, \u003cb\u003e59\u003c/b\u003e(4):519-521.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDombrauckas JD, Santarsiero BD, Mesecar AD: \u003cb\u003eStructural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis\u003c/b\u003e. \u003cem\u003eBiochemistry\u003c/em\u003e 2005, \u003cb\u003e44\u003c/b\u003e(27):9417\u0026ndash;9429.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDayton TL, Jacks T, Vander Heiden MG: \u003cb\u003ePKM2, cancer metabolism, and the road ahead\u003c/b\u003e. \u003cem\u003eEMBO Rep\u003c/em\u003e 2016, \u003cb\u003e17\u003c/b\u003e(12):1721\u0026ndash;1730.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen CH, Wen J, Asara J, McGraw TE \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eAMPK\u003c/b\u003e-\u003cb\u003edependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1\u003c/b\u003e. \u003cem\u003eMol Cell\u003c/em\u003e 2013, \u003cb\u003e49\u003c/b\u003e(6):1167-1175.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSalomon AR, Voehringer DW, Herzenberg LA, Khosla C: \u003cb\u003eUnderstanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase\u003c/b\u003e. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e 2000, \u003cb\u003e97\u003c/b\u003e(26):14766\u0026ndash;14771.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBuac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, Neslund-Dudas C, Mitra B, Dou QP: \u003cb\u003eFrom bortezomib to other inhibitors of the proteasome and beyond\u003c/b\u003e. \u003cem\u003eCurr Pharm Des\u003c/em\u003e 2013, \u003cb\u003e19\u003c/b\u003e(22):4025\u0026ndash;4038.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuo N, Peng Z: \u003cb\u003eMG132, a proteasome inhibitor, induces apoptosis in tumor cells\u003c/b\u003e. \u003cem\u003eAsia Pac J Clin Oncol\u003c/em\u003e 2013, \u003cb\u003e9\u003c/b\u003e(1):6\u0026ndash;11.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJin X, Pan Y, Wang L, Zhang L, Ravichandran R, Potts PR, Jiang J, Wu H, Huang H: \u003cb\u003eMAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation\u003c/b\u003e. \u003cem\u003eOncogenesis\u003c/em\u003e 2017, \u003cb\u003e6\u003c/b\u003e(4):e312.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen SJ, Wu X, Wadas B, Oh JH, Varshavsky A: \u003cb\u003eAn N-end rule pathway that recognizes proline and destroys gluconeogenic enzymes\u003c/b\u003e. \u003cem\u003eScience\u003c/em\u003e 2017, \u003cb\u003e355\u003c/b\u003e(6323).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchork SM, Bee G, Thumm M, Wolf DH: \u003cb\u003eCatabolite inactivation of fructose-1,6-bisphosphatase in yeast is mediated by the proteasome\u003c/b\u003e. \u003cem\u003eFEBS Lett\u003c/em\u003e 1994, \u003cb\u003e349\u003c/b\u003e(2):270\u0026ndash;274.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHorak J, Regelmann J, Wolf DH: \u003cb\u003eTwo distinct proteolytic systems responsible for glucose-induced degradation of fructose-1,6-bisphosphatase and the Gal2p transporter in the yeast Saccharomyces cerevisiae share the same protein components of the glucose signaling pathway\u003c/b\u003e. \u003cem\u003eJ Biol Chem\u003c/em\u003e 2002, \u003cb\u003e277\u003c/b\u003e(10):8248\u0026ndash;8254.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSpinelli JB, Yoon H, Ringel AE, Jeanfavre S, Clish CB, Haigis MC: \u003cb\u003eMetabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass\u003c/b\u003e. \u003cem\u003eScience\u003c/em\u003e 2017, \u003cb\u003e358\u003c/b\u003e(6365):941\u0026ndash;946.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGhanem A, Melzer AM, Zaal E, Neises L, Baltissen D, Matar O, Glennemeier-Marke H, Almouhanna F, Theobald J, Abu El Maaty MA \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eAscorbate kills breast cancer cells by rewiring metabolism via redox imbalance and energy crisis\u003c/b\u003e. \u003cem\u003eFree Radic Biol Med\u003c/em\u003e 2021, \u003cb\u003e163\u003c/b\u003e:196-209.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShi L, He C, Li Z, Wang Z, Zhang Q: \u003cb\u003eFBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1alpha\u003c/b\u003e. \u003cem\u003eNeoplasma\u003c/em\u003e 2017, \u003cb\u003e64\u003c/b\u003e(4):535\u0026ndash;542.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIcard P, Fournel L, Coquerel A, Gligorov J, Alifano M, Lincet H: \u003cb\u003eCitrate targets FBPase and constitutes an emerging novel approach for cancer therapy\u003c/b\u003e. \u003cem\u003eCancer Cell Int\u003c/em\u003e 2018, \u003cb\u003e18\u003c/b\u003e:175.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang J, Jin X, Yan Y, Shao Y, Pan Y, Roberts LR, Zhang J, Huang H, Jiang J: \u003cb\u003eInhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression\u003c/b\u003e. \u003cem\u003eSci Rep\u003c/em\u003e 2017, \u003cb\u003e7\u003c/b\u003e:43864.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSun N, Youle RJ, Finkel T: \u003cb\u003eThe Mitochondrial Basis of Aging\u003c/b\u003e. \u003cem\u003eMol Cell\u003c/em\u003e 2016, \u003cb\u003e61\u003c/b\u003e(5):654\u0026ndash;666.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBratic A, Larsson NG: \u003cb\u003eThe role of mitochondria in aging\u003c/b\u003e. \u003cem\u003eJ Clin Invest\u003c/em\u003e 2013, \u003cb\u003e123\u003c/b\u003e(3):951\u0026ndash;957.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu Y, Jiang Y, Wang N, Jin Q, Ji F, Zhong C, Zhang Z, Yang J, Ye X, Chen T: \u003cb\u003eInvalidation of mitophagy by FBP1-mediated repression promotes apoptosis in breast cancer\u003c/b\u003e. \u003cem\u003eTumour Biol\u003c/em\u003e 2017, \u003cb\u003e39\u003c/b\u003e(6):1010428317708779.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVancura A, Bu P, Bhagwat M, Zeng J, Vancurova I: \u003cb\u003eMetformin as an Anticancer Agent\u003c/b\u003e. \u003cem\u003eTrends Pharmacol Sci\u003c/em\u003e 2018, \u003cb\u003e39\u003c/b\u003e(10):867\u0026ndash;878.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHunter RW, Hughey CC, Lantier L, Sundelin EI, Peggie M, Zeqiraj E, Sicheri F, Jessen N, Wasserman DH, Sakamoto K: \u003cb\u003eMetformin reduces liver glucose production by inhibition of fructose\u003c/b\u003e-\u003cb\u003e1\u003c/b\u003e-\u003cb\u003e6\u003c/b\u003e-\u003cb\u003ebisphosphatase\u003c/b\u003e. \u003cem\u003eNat Med\u003c/em\u003e 2018, \u003cb\u003e24\u003c/b\u003e(9):1395-1406.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLaemmli UK: \u003cb\u003eCleavage of structural proteins during the assembly of the head of bacteriophage T4\u003c/b\u003e. \u003cem\u003eNature\u003c/em\u003e 1970, \u003cb\u003e227\u003c/b\u003e(5259):680\u0026ndash;685.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVichai V, Kirtikara K: \u003cb\u003eSulforhodamine B colorimetric assay for cytotoxicity screening\u003c/b\u003e. \u003cem\u003eNat Protoc\u003c/em\u003e 2006, \u003cb\u003e1\u003c/b\u003e(3):1112\u0026ndash;1116.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZou C, Wang Y, Shen Z: \u003cb\u003e2-NBDG as a fluorescent indicator for direct glucose uptake measurement\u003c/b\u003e. \u003cem\u003eJ Biochem Biophys Methods\u003c/em\u003e 2005, \u003cb\u003e64\u003c/b\u003e(3):207\u0026ndash;215.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, Vasquez-Vivar J, Kalyanaraman B: \u003cb\u003eSuperoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide\u003c/b\u003e. \u003cem\u003eFree Radic Biol Med\u003c/em\u003e 2003, \u003cb\u003e34\u003c/b\u003e(11):1359\u0026ndash;1368.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR: \u003cb\u003eBortezomib resistance in multiple myeloma is associated with increased serine synthesis\u003c/b\u003e. \u003cem\u003eCancer Metab\u003c/em\u003e 2017, \u003cb\u003e5\u003c/b\u003e:7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBauer AS, Nazarov PV, Giese NA, Beghelli S, Heller A, Greenhalf W, Costello E, Muller A, Bier M, Strobel O \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eTranscriptional variations in the wider peritumoral tissue environment of pancreatic cancer\u003c/b\u003e. \u003cem\u003eInt J Cancer\u003c/em\u003e 2018, \u003cb\u003e142\u003c/b\u003e(5):1010\u0026ndash;1021.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePerelman A, Wachtel C, Cohen M, Haupt S, Shapiro H, Tzur A: \u003cb\u003eJC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry\u003c/b\u003e. \u003cem\u003eCell Death Dis\u003c/em\u003e 2012, \u003cb\u003e3\u003c/b\u003e:e430.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Scheme","content":"\u003cp\u003eSchemes 1 and 2 are available in the Supplemental Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"gluconeogenic, metabolic, suppressor, cancers, breast tumours","lastPublishedDoi":"10.21203/rs.3.rs-1030616/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1030616/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe key gluconeogenic enzyme Fructose 1,6 bisphosphatase has emerged as a potential metabolic tumour suppressor in recent years. Ablation of FBP1 expression in various tumours fosters metabolic rewiring towards an increased reliance on aerobic glycolysis. While FBP1 is completely repressed in many cancers, breast tumours display distinct FBP1 expression based on their subtype, hence making breast cancer a suitable model for discerning the effects of FBP1 in contexts of cancer initiation and progression. We used ectopic over-expression and CRISPR-Cas9 disruption to establish cell lineages with stable alterations in their FBP1 levels. Complete knock-outs of FBP1 on gene level confirm the major impact of FBP1 on cancer cell metabolism and proliferation. Moreover, our results reveal cancer subtype-specific peculiarities in response to ectopic FBP1 expression including a clear demonstration of an adaptive proteasomal degradation of FBP1 in breast cancer cells, which is regulated by glucose and nutrient availability. In addition to validating the suggested tumour suppressor role of FBP1, our findings demonstrate an efficient adaptive complex regulation of FBP1 expression and its impact on the adaptation of cancer cells to nutrient conditions. Our results highlight the importance of FBP1 ablation on the protein level and its potential relevance to cancer and beyond.\u0026nbsp;\u003c/p\u003e","manuscriptTitle":"Genetic Manipulation of FBP1 Expression in Breast Cancer Cells Reveals the Potential of FBP1 to Disrupt The Warburg Effect, and Nutrient Mediated Adaptive Post-Translational Regulation of FBP1 Protein Levels.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2021-11-16 15:12:46","doi":"10.21203/rs.3.rs-1030616/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"da2d3b6d-5bdf-4a35-9d3a-009747c38195","owner":[],"postedDate":"November 16th, 2021","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":8538465,"name":"Cancer Biology"},{"id":8538466,"name":"Cellular Metabolism"}],"tags":[],"updatedAt":"2022-02-24T12:56:05+00:00","versionOfRecord":[],"versionCreatedAt":"2021-11-16 15:12:46","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1030616","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1030616","identity":"rs-1030616","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}